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Molecular analysis of the cross talk between Angiotensin II (Ang II) and insulin
signaling systems reveal that they are multifaceted and occur at cellular level and
intracellular level. Experiments were carried out to evaluate the crosstalk between the
Ang II receptors-AT1 and AT2 and the Insulin Receptor (IR) to understand the changes
in the signaling pathway that could lead to the transition from hypertension to insulin
resistance. Transient expression of rat AT2 in CHO cells induced coimmunoprecipitation of the AT2R with IRȕ and inhibition of IRȕ tyrosine
phosphorylation. An AT2-peptide carrying the amino acids 226-363 (that spans 3rd
intracellular loop (ICL) and C-terminal cytoplasmic domain) was sufficient for AT2- IRȕ
interaction in a yeast two-hybrid assay. An orthovanadate-insensitive AT2- IRȕ
association was also observed in human breast cancer cell line MCF-7. Interestingly,
while AT2- IRȕ complex formation was insensitive to pertussis toxin (PTX), AT2-

mediated inhibition of IRȕ phosphorylation was partially sensitive to PTX treatment in
MCF-7.
To address the mechanism behind the transition of an early hypertensive heart to
an insulin resistant status, we investigated the changes that occur at post translational
level in the IR and its downstream signaling molecules that modulate insulin signaling.
Early hypertension was induced in 10-week old SD rats by 2% NaCl diet in combination
with Ang II infusion. Enhanced serine phosphorylation of the IRȕ suggestive of
dysfunctional insulin signaling was observed in cardiac tissues as a result of the
treatment. In addition, an enhanced association of both AT1R and AT2R with IRȕ was
observed in the heart tissue lysates from hypertensive rat heart.
To evaluate the tissue effects of Ang II, we compared the transcriptome of
hypertensive rat hearts to the controls. Analysis suggests that the Ang II induces multiple
responses in heart tissue that result in changes to the gene expression pattern intended to
promote insulin sensitivity and insulin resistance. Taken together our results suggest that
exogenous Ang II and moderately high salt diet promote metabolic abnormalities in heart
tissue that result in sequestration of IR and modulation of IR signaling, and significant
changes in gene expression profile in the hypertensive heart.
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CHAPTER I
INTRODUCTION

The pathway from hypertension to insulin resistance and then to diabetes and
cardiovascular diseases is a complex mechanism that poses a major threat to the
population and if untreated, will result in an increased risk for various life-threatening
complications that encompasses the whole array of metabolic syndrome (Figure 1.1).
Lifestyle and genetic factors are important in the genesis of both hypertension and insulin
resistance. An estimated 3 million Americans have both diabetes and hypertension which
predisposes them to a higher risk of cardiovascular and renal diseases. Metabolic
syndrome is characterized by a constellation of factors that include hypertension,
hyperglycemia, dyslipidemia, high waist circumference and
proinflammatory/prothrombotic conditions. Resistance to the actions of insulin is an
important underlying mechanism in the development of insulin resistance. The important
organs that are affected by metabolic syndrome include the vasculature, heart, skeletal
muscle, adipose tissue and liver (1).
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Blood
Pressure
>130mmHg
or 85mmHg

Glucose
> 5.6mmol/L

HDL
< 1.03mmol/L
in men
< 1.29mmol/L
in women

LDL
TG
> 1.7mmol/L

Waist cirumference
>102 cm in men
> 88cm in women

Inflammation/
Thrombosis

Figure 1.1:

Metabolic Syndrome: Associated risk factors

Since the pathological changes that underlie diabetes and hypertension begin
much before the clinical symptoms develop it is essential to identify early genetic,
molecular and cellular changes that promote the development of these diseases. The coexistence of insulin resistance and hypertension may be explained by the coincidence of
two common abnormalities, the causation of one by other, or a common underlying
factor. A potential relation between insulin resistance and hypertension could be
mediated by the renin angiotensin system (RAS).
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1.1 The Renin angiotensin system:

1.1.1

Historical background
The first clinical evidence for correlation between cardiac hypertrophy and renal

disease was reported in 1836 by Richard Bright (2). However, the first insight into the
regulation of blood pressure came 61 years later from the discovery of a pressor principle
termed “renin” by Tigerstedt and Bergman. Subsequent studies further elucidated this
system that caused vasoconstriction and in 1940 Page and Helmer identified a “renin
activator” that later proved to be angiotensinogen. The pressor substance produced as a
result of the action of renin on angiotensinogen was called “hypertensin” in Argentina
and “angiotonin” in United States. In 1957, this substance was isolated and characterized
as an octapeptide by various groups (2). The two groups later arrived at a single
nomenclature- Angiotensin. Following this major discovery, all the components of the
pathway that lead to an increase in blood pressure including angiotensinogen, angiotensin
converting enzyme (ACE) and Angiotensin I, II and III were isolated and characterized.
A schematic overview of the RAS is shown in figure 1.2.
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Angiotensinogen
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser
Renin
Cathepsin D &G
ACE2
Angiotensin I (1-10)
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu

Ang 1-9
ACE1

ACE1

Chymase
Cathepsin G
Angiotensin II (1-8)
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe

Ang 1-7
Asp-Arg-Val-Tyr-Ile-His-Pro

Ang IV
Ang III
Val-Tyr-Ile-His-Pro-Phe Arg-Val-Tyr-Ile-His-Pro-Phe

AT4-R

Figure 1.2:

AT1-R, AT2-R

AT1-7-R

Renin Angiotensin System: Classical pathway

The RAS exerts a wide range of effects on cardiovascular homeostasis and blood
pressure. The RAS is generally activated when there is a drop in blood pressure due to
hypovolemia or heamorrage. Under these conditions, juxtaglomerular cells in the kidneys
release the enzyme renin. Renin then cleaves the inactive peptide angiotensinogen, which
is produced in the liver, and converts it to Angiotensin I. Ang I is able to alter the blood
pressure to a certain extent, but most of it is converted to the major effector peptide of
this system- Angiotensin II by ACE1. Even though ACE1 is the major enzyme that
converts Ang I to Ang II, in heart, the majority of the Ang II generation is by chymase
(3). ACE2 is a recently identified carboxypeptidase that cleaves one amino acid from
Ang I or Ang II to generate metabolite Ang 1-7 which has vasodilator properties (4-8).
Thus a balance between ACE1 and ACE2 regulates the levels of Ang II in the blood.
Activation of Ang II via RAS results in constriction of blood vessels, an increase in the
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secretion of anti-diuretic hormone (ADH) and stimulation of the hypothalamus to activate
the thirst reflex and thereby increases the blood pressure.
Ang II, an octapeptide hormone, is the active component of the RAS Figure 1.3.
This primary effector molecule of the system has an effect on almost all organs including
the heart, kidney, vasculature and brain and it has both beneficial and pathological effects
(9). Ang II plays a key role in cardiovascular homeostasis by regulating blood volume
and vascular resistance. Although Ang II is classically known as a vasoconstrictor agent,
it is now known that it has potent growth and proinflammatory actions. Ang II is not only
a blood borne hormone that is present in circulation but is produced in various tissues
such as heart, brain, kidney, adipose tissue and blood vessel. Thus RAS can function not
only in the classical endocrine manner, but also as an autocrine and/or paracrine
hormone, which can induce cell growth and proliferation and control extracellular matrix
formation. (10-12) Other Angiotensin II derived metabolites such as Ang 2-8 (Ang III)
and Ang 3-8 (Ang IV) have been shown to have pressor activity, whereas the Ang 1-7 is
a known vasodilator. In vitro and in vivo studies performed using structurally modified
peptides to determine the affinity and biological activity shows that Ang II is highly
dependent on the conformational and dynamic properties of the tyrosine-4/histidine-6
side groups and the phenyl ring of the phenylalanine-8 and the free COOH group at the
carboxy terminus. The N-terminal residues are important for receptor binding and the
duration of action of Ang II agonists but are not specifically required for biological
activity. NMR analyses of Ang II and its peptide analogs yielded models for the spatial
arrangement of the four pharmacophore groups, Tyr4, His6, Phe8, and the C terminal
carboxyl group, that determine the biologically active conformation of the peptide (13,
5

14). These studies indicated that the three aromatic rings cluster together and suggested
that a bend in the Tyr-Ile-His region of the molecule is a prominent feature of its
agonistic conformation. The Ang II (2–8) heptapeptide (Ang III) formed by deletion of
the Asp1 residue is almost as potent as the native octapeptide. The Ang II (3–8)
hexapeptide (Ang IV) also retain full biological efficacy but is a weak agonists due to its
low-binding affinity for the AT1 receptor. The Ang II (1–7) heptapeptide also binds to
the receptor with low affinity, but has no agonist activity in most Ang II target cells, and
is accordingly a weak Ang II antagonist in vitro (15-23). Given the diverse range of
functions and its potency in cardiovascular physiology, it is important to understand Ang
II receptors and the Ang II mediated signal transduction.

Figure 1.3:

Space filling model: Ang II Asp-Arg-Val-Tyr-Ile-His-Pro-Phe (24)
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1.1.2 Characterization of angiotensin receptors
The multiple actions of Ang II are mediated following an initial binding of the
hormone to cell surface receptors. The two major high affinity receptor subtypes that
regulate the vascular smooth muscle action are Angiotensin II type I receptor (AT1R) and
Angiotensin II type II receptor (AT2R) (25, 26). These two receptors can be
distinguished based on their inhibition by specific antagonist losartan and PD123319 (2731). Two other receptors AT3 and AT4 have been identified although they have not yet
been fully characterized. The AT3 receptor subtype which was initially described in the
neuro 2A neuroblastoma cell line is peptide-specific, recognizing mainly Ang II (32). The
AT4 receptor, which is distributed in heart, lung, kidney, brain, and liver, binds Ang IV
but not losartan or PD123319 (33).
Ang II receptors AT1 and AT2 belong to the G protein coupled receptor (GPCR)
superfamily. Hydropathy analysis indicated that both the receptors have seven
transmembrane segments that form alpha helices in the lipid bilayer of the cell
membrane. The two receptors share approximately 32-34% sequence homology (Figure
1.4) and are highly regulated in a developmental, tissue-specific and disease-specific
context (34, 35).
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AGTR1_HUMAN MILNSSTEDGIKRIQD-----------------DCPKAGRHNYIFVMIPT 33
AGTR2_HUMAN MKGNSTLATTSKNITSGLHFGLVNISGNNESTLNCSQK-PSDKHLDAIPI 49
AGTR1_HUMAN LYSIIFVVGIFGNSLVVIVIYFYMKLKTVASVFLLNLALADLCFLLTLPL 83
AGTR2_HUMAN LYYIIFVIGFLVNIVVVTLFCCQKGPKKVSSIYIFNLAVADLLLLATLPL 99
AGTR1_HUMAN WAVYTAMEYRWPFGNYLCKIASASVSFNLYASVFLLTCLSIDRYLAIVHP133
AGTR2_HUMAN WATYYSYRYDWLFGPVMCKVFGSFLTLNMFASIFFITCMSVDRYQSVIYP 149
AGTR1_HUMAN MKSRLRRTMLVAKVTCIIIWLLAGLASLPAIIHRNVFFIENTNITVCAFH 183
AGTR2_HUMAN FLS-QRRNPWQASYIVPLVWCMACLSSLPTFYFRDVRTIEYLGVNACIMA 198
AGTR1_HUMAN YESQ-NSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYEIQKNK 232
AGTR2_HUMAN FPPEKYAQWSAGIALMKNILGFIIPLIFIATCYFGIRKHLLKTNSYGKNR 248
AGTR1_HUMAN PRNDDIFKIIMAIVLFFFFSWIPHQIFTFLDVLIQLGIIRDCRIADIVDT 282
AGTR2_HUMAN ITRDQVLKMAAAVVLAFIICWLPFHVLTFLDALAWMGVINSCEVIAVIDL 298
AGTR1_HUMAN AMPITICIAYFNNCLNPLFYGFLGKKFKRYFLQLLKYIPPKAKSHSNLST 332
AGTR2_HUMAN ALPFAILLGFTNSCVNPFLYCFVGNRFQQKLRSVFRVP------ITWLQG 342
AGTR1_HUMAN KMSTLSYRPSDNVSSSTKKPAPCFEVE 359
AGTR2_HUMAN KRESMSCRKSSSLREMETFVS------ 363

Figure 1.4:

Amino acid sequence comparison of AT1R and AT2R using
ClustalW2 multiple sequence alignment

AT1R is the major receptor expressed in adult tissues whereas AT2R is the
dominant receptor expressed in fetal tissues (36, 37). Most of the known physiological
effects of Ang II such as vasoconstriction, facilitation of sympathetic transmission,
sodium retention, stimulation of aldosterone release and promotion of cellular growth are
mediated via the AT1R (38, 39). Ang II acting via AT2R on the other hand brings about
modulation of various biological processes involved in development, differentiation,
tissue repair, natriuresis and apoptosis (40-42).
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1.1.3

Angiotensin II type I receptor
The AT1 receptor was initially cloned from rat smooth muscle and bovine adrenal

gland (43). The AT1R (40 kDa) is composed of 359 amino acids and belongs to the
seven-transmembrane containing superfamily of GPCRs. The human AT1R gene
(AGTR1) is present on chromosome 3. The receptor is the product of a single gene that
contains five exons and the size ranges from 59 to 2014bp. The open reading frame of the
AT1R is located in exon 5. In rat, two isoforms have been identified: the AT1aR on
chromosome 17 and the AT1bR on chromosome 2 (44). These two isoforms share 95%
amino acid sequence identity. Although the two receptor subtypes are similar in their
sequence, in vivo experiments show that the AT1aR isoform could play an important role
than AT1bR in regulating blood pressure (45). There are three glycosylation sites on the
extracellular domain of the AT1 receptor and mutation of these sites has no effect on
agonist binding (46). Four cysteine residues located on the extracellular region of the
AT1R form disulfide bridges and are considered essential for Ang II binding (47). The
AT1 receptor’s cytoplasmic tail can be phosphorylated by G protein receptor kinases or
(GRKs) due to the presence of several serine/threonine residues. These sites may be
crucial in altered receptor function in cardiovascular disease. The amino acid sequence
and the structural organization of the AT1 receptor is given in figure 1.5.
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Figure 1.5:

Secondary structure and consensus sequence of the mammalian
AT1 receptor.
The amino acid sequence shown is based on the derived sequences
of five individual cloned mammalian AT1 receptors. The amino
acid residues that are highly conserved among G protein-coupled
receptors are indicated by bold letters. (42)

According to the CLUSTAL studies performed on the alignment of cloned AT1R
sequences, the rat and mouse AT1 receptors have coevolved (48), while amphibian and
avian receptors diverged early during evolution. Paralogs arising as a result of gene
duplication has been observed in rats and mice. In humans, alternative splicing of the
gene has been suggested to generate two isoforms with similar binding and function
properties (49). The amino acid sequence of human AT1R is 95% similar to rat and
bovine AT1 receptors.
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Cardiovascular diseases have been linked to genetic changes in the RAS signaling
system. Ang II mediated effects vary among individuals based on their genetic make up.
Gene mapping studies have discovered several single nucleotide polymorphisms (SNPs)
of the AT1R gene that have been linked to an increased development of cardiovascular
risk factors. One of the several polymorphisms, the A1166C polymorphism of the AT1R
gene has been implicated in hypertension (50), increased aortic stiffness (51), and
myocardial infarction (52). An association between A1166C polymorphism and Ang II
sensitivity has been shown in high salt induced hypertensive condition (53). Mutation of
the AT1 receptor results in an increased response to Ang II and increased
vasoconstriction in isolated arteries (54). However, due to the inconsistency in the reports
on the effect of polymorphism, the studies remain inconclusive (55). An association of
the SNP with hyperlipidemia is found in patients with familial hypercholesterolemia, a
polygenic genetic condition in which there is a decrease in the number of LDL receptors.
In such conditions, the A1166C SNP may increase the risk of coronary heart disease (56).
Both expression levels and the numbers of the AT1 receptor vary considerably
among different tissues with different pathological conditions like hypertension, after
myocardial infarction and during the process of heart remodeling (57, 58). Relatively
little is known about the control of expression of the AT1 receptor in most Ang II target
tissues in the human. Both Ang II and its AT1 and AT2 receptor types are present in the
endometrium of the reproductive system, and exhibit cyclic changes during the menstrual
cycle with a maximum in the early secretory phase (59). AT1 receptors are expressed in
the glands and the endometrial blood vessels and may participate in uterine vascular
regulation and regeneration of the endometrium after menstruation. The AT1 receptor is
11

found in the circumventricular organ, thalamus, basal ganglia, cerebellar cortex and
medulla oblongata. The human placenta expresses the AT1 receptor and all other
components of the renin-angiotensin system. (60). Expression of the human AT1 receptor
is enhanced by epidermal growth factor in COS cells (61). The human adipose tissue has
a local RAS with expression of angiotensinogen, ACE and AT1 receptor in omental, sub
cutaneous fat and cultured adipocytes (62). The renal vasculature along with the
glomeruli and the vasa recta bundles express high levels of the AT1 receptors (63).
In rat, studies on the tissue specific AT1 receptor expression revealed that the
lungs, liver and heart solely contain AT1A receptor whereas the anterior pituitary gland
contains the AT1B receptor. In the adult mouse AT1A receptors are expressed in the
kidney, liver, adrenal gland, ovary, brain, testis, lung, heart, and adipose tissue. In
contrast, AT1B receptors are confined to the adrenal gland, brain, and testis (37, 64). The
two external disulfide bonds and several other residues located on the exposed surfaces of
the AT1 receptor are essential for Ang II binding. Other residues that are involved in Ang
II binding include the Lys102 at the top of transmembrane helix III and Lys199 near the top
of TM helix V that are located in the hydrophobic transmembrane domain. The additional
disulfide bridge between the amino terminal region and the third extracellular loop of the
AT1 receptor plays a role in stabilizing the receptor and to maintain the proximity of the
extracellular amino acids that are involved in peptide binding. AT1 receptor binding can
be impaired by cleavage of this disulfide bond (47). Ang II binding to the AT1 receptor
involves interaction with residues in its N terminus and its first and third extracellular
loops (65). In addition, the transmembrane helices also contribute to Ang II binding
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through its C-terminal carboxyl group, which interacts with Lys199 in the upper part of
helix 5 of the receptor.
The ultimate effects of Ang II on the target tissue are mainly carried out by the
AT1 receptor and therefore it is necessary to understand the mechanism that regulates
AT1 density within the plasma membrane. Increased levels of Ang II leads to an increase
in receptor activation, however a chronic exposure to Ang II will result in a
downregulation of its own receptors through a negative feedback control mechanism (66,
67). A link between various disorders such as hyperlipidemia/hyperinsulinemia and
hypertension can be deduced by studying the mechanism of AT1R regulation. It is known
that LDL and insulin can upregulate AT1R gene expression by post-transcriptional
mRNA stabilization (68-71).
The effect of Ang II on its tissue is transient and the tissue is desensitized to further
agonism. One of the major mechanisms by which the receptor is desensitized is via the
phosphorylation of the several Ser/Thr residues on the cytoplasmic side of the receptor by
GRKs. The AT1R is internalized within 10minutes of activation. Approximately 25% of
the receptors are recycled back to the plasma membrane while the remainder is degraded
in lysosomes (72, 73). ȕ arrestins, G protein-mediated phospholipase D2 and Rab family
of proteins are thought to play a role in coordinating the process of internalization and
recycling (74).

1.1.4

AT1 receptor signaling
Ang II-AT1R interaction activates a series of signaling cascades, which in turn

regulate the various physiological effects of Ang II. One well established mechanism by
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which Ang II signaling occurs involves the classic G protein-mediated pathways as
shown in figure 1.6. In addition, Ang II mediated activation of the AT1R can also act
beyond G protein mediated mechanisms and is known to mediate signaling through
several receptor tyrosine kinases, including receptor tyrosine kinases [EGFR, PDGF, IR]
and nonreceptor tyrosine kinases [c-Src family kinases, Ca2+dependent proline-rich
tyrosine kinase 2 (Pyk2), focal adhesion kinase (FAK) and Janus kinases (Jak) (Figure
1.7). Actions of Ang II in the vasculature occur via activation of NAD(P)H oxidases and
generation of reactive oxygen species (ROS) (75). AT1R mediated cell growth and
hypertrophy are the result of activation of serine/threonine kinases such as PKC and
MAPKs [including ERK1/2, p38MAPK and c-Jun NH2-terminal kinase (JNK)]. Under
conditions where RAS is over stimulated or there is an enhanced responsiveness to Ang
II, these pathways may initiate and propagate pathological events promoting vascular
disease (76). Studies on the temporal and spatial pattern of signaling shows that the
activation of different pathways by Ang II is time dependent. For example, activation of
the G protein-dependent pathway and generation of IP3 occurs in seconds, while MAP
kinase and Jak/STAT activation occurs in minutes to hours after initial activation of
AT1R (77, 78).
Ang II induced vasoconstriction is mediated by “classical” G protein-dependent
signaling pathways (Figure 1.6). Experimental evidence shows that activation of the
AT1R leads to coupling to GĮq/11, GĮ12/13, and GȕȖ complexes (79), which activate
downstream effectors including phospholipase C (PLC), phospholipase A2 (PLA2), and
phospholipase D (PLD) (80). Activation of PLC produces inositol-1, 4, 5-triphosphate
(IP3) and diacylglycerol (DAG) within seconds. IP3 increases the calcium efflux into the
14

cytoplasm which will result in Ca2+ binding to calmodulin and activating myosin light
chain kinase (MLCK). MLCK phosphorylates the myosin light chain and enhances the
interaction between actin and myosin, causing smooth muscle cell contraction (81).
myosin light chain phosphatases (MLCP) regulate the action of MLCK on myosin.
MLCP is inhibited by Rho kinase leading to sustained contraction (82). Activation of
PKC via Ang II has also been shown to increase phosphorylation of CPI-17 (a MLCP
inhibitor) (83). Activation of PKC by DAG signaling also participates as an effector in
the Ras/Raf/MEK/ERK pathway. The vasoconstrictive properties and growth promoting
characteristics of Ang II are brought about by these downstream signaling molecules.
Activation of the AT1R also leads to PLD activation which results in hydrolysis of
phosphatidylcholine (PC) to choline and phosphatidic acid (PA). PA is rapidly converted
to DAG; DAG activates PKC and results in sustained vasoconstriction. In hypertensive
rats, the PLC/PLD pathways causing muscle contraction are increased compared with
controls, suggesting a role for the G protein-activated second messengers in the
pathogenesis of hypertension (84, 85).
Ang II mediated phosphorylation and activation of PLA2 leads to production of
arachidonic acid (AA) and its metabolites. AA derivatives function to maintain vascular
tone and plays a role in VSMC NAD(P)H oxidation (75). Ang II acting via
lipooxygenase also mediates the formation of leukotrienes, implicated in
vasoconstriction, hypertension, and inflammatory diseases (86).
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Figure 1.6:

Role of Ang II in vascular smooth muscle contraction via G
protein signaling (9)

Ang II has also been shown to activate signaling cascades that activate MAPKs,
including extracellular signal regulated kinase (ERK1/2), JNK, and p38MAPK, which are
implicated in VSMC differentiation, proliferation, migration, and fibrosis (87, 88). Even
though AT1 does not have an intrinsic tyrosine kinase activity, it is known that non
receptor tyrosine kinases and receptor tyrosine kinases can associate with and initiate
signaling events that lead to downstream signaling of various proteins. A variety of
pathways such as Ras, FAK, Jak/STAT, and PLCȖ (leading to sustained calcium release)
are activated by c-Src kinase, a tyrosine kinase that is activated by GȕȖ. The ligand
activated AT1R also induces the Jak/STAT mitogenic pathway. STAT proteins can
dimerize via sulfhydryl-phosphotyrosine interactions and translocate to the nucleus,
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where they can mediate gene transcription of early growth response genes, such as c-fos
and c-myc (89). Ang II stimulated association of Jak2 with AT1R occurs when Jak2
docks to the COOH terminus, specifically the YIPP motif, of the AT1R and stimulates
Jak2 phosphorylation at Tyr1007/1008 (90, 91). SHP-1 dephosphorylates Jak2 and
thereby blocks Ang II-activated Jak/STAT signaling (92). Actions of Ang II via
Jak/STAT signaling results in Ang II mediated multifaceted events like VSMC growth,
migration, and remodeling. AT1R can also transactivate RTKs such as PDGF, EGFR and
IR. Ang II mediated PDGF receptor phosphorylation via Shc is a Ca2+ independent event
(93). Ang II infusion results in stimulation of rat aortic smooth muscle cells to induce the
formation of a Shc and Grb2 complex with the PDGF receptor independent of PDGF
(94). Several common pathways (such as MAPK and PLC) are involved in PDGFR and
Ang II signaling, that are implicated in VSMC hypertrophy. Growth related signaling of
Ang II mediated via PDGFR is a mechanism that is independent of PDGF binding to the
receptor. Another mechanism of growth related signaling via Ang II is the transactivation
of EGFR (95, 96). Activation of EGFR results in the docking of Grb2/Shc/Sos complexes
inducing the PI3K/PDK1/Akt cascade, which leads to cellular metabolism, growth,
survival, and remodeling, and the Ras/Raf/ERK pathway which leads to cell growth,
hypertrophy, and inflammation. Kagiyama et al. reported that rats treated with an
intravenous infusion of antisense oligodeoxynucleotide to EGFR results in an attenuation
of Ang II-mediated hypertension and left ventricular hypertrophy. (97). A number of
studies have been performed to understand the cross talk between Ang II and insulin.
Ang II can also influence signal transduction mediated via IR signaling pathway. In vivo
studies in rats show that infusion of Ang II induces insulin resistance (98, 99); patients
17

with an imbalance in RAS homeostasis exhibit decreased insulin sensitivity (100).
Interestingly, antihypertensive drugs such as ACE inhibitors and ARBs improves insulin
resistance and diabetic complications suggesting a crosstalk between the two systems
(101, 102).

Figure 1.7:

1.1.5

Ang II mediated cell growth and hypertrophy

Angiotensin II type 2 receptor
As evident from the above sections, while a great deal is known about the AT1R,

there is much less information regarding the AT2R and the field is still a matter of intense
research. The AT2R is very distinct from the AT1R in tissue specific expression and
signaling. The AT2R was cloned in 1993 from rat PC12W cells by Kambayashi et al. and
from rat fetuses by Nakajima et al (103, 104). Ichiki et al. and Nakajima et al. cloned the
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mouse AT2 cDNA from a mouse fetal library and Tsuzuki et al cloned the human AT2
coding sequence (105, 106). The genomic DNA of all three species consists of three
exons with an uninterrupted coding region in the third exon. The genes encoding the
AT2R are located on the X chromosome in all three species. The open reading frame of
the AT2 receptor encodes a 363 amino acid receptor that belongs to the GPCR
superfamily (Figure 1.8). The sequence comparisons reveal a high level of homology
with 99% sequence identity between rat and mouse and 79% identity between rat and
human. The divergence between the rodent and the human sequence lies in the amino
terminus. The amino acid sequence indicates that it has five potential N glycosylation
sites. The AT2 receptor has only 34% sequence identity with the AT1 receptor (103, 104)
that was mainly localized to the hydrophobic transmembrane (TM) domains. Residues
located in these transmembrane helical column domains that are considered to be
essential for Ang II binding to the AT1 receptor are also preserved in the AT2 receptor.
Some of these include Lys118 (Lys102 of AT1) at the top of TM3, Arg183 (Arg167 of
AT1) at the top of TM4 and Lys216 (Lys199 of AT1). The extensive differences between
the AT1 and AT2 receptors are observed in the third intracellular loop and in the
carboxyl terminal tail (42).
The AT2R is predominantly expressed in the fetal tissues. The AT2R emerges on
embryonic days 11 to 13 and reaches a maximum level by day 19. The AT2R then
rapidly declines in newborn animals to lower levels (adrenals or heart) or undetectable
levels (skin). The AT2R expression could be regulated at a transcriptional or post
transcriptional level. The AT2R binding sites increase in confluent R3T3 cells without an
increase in mRNA while it is high before achieving confluence (107). The AT2 receptor
19

in these cells activates protein phosphotyrosine phosphatases (PTP), which may play a
role in AT2 mediated inactivation of mitotic or hypertrophic growth. Even though AT1
mediated internalization has been shown, this receptor lacks an internalization and
desensitization mechanism which is probably helps in maintaining differentiated cells in
a quiescent state (108). Expression of the AT2R is also dependent on growth factors or
growth states. In R3T3 cells, the AT2R mRNA is expressed when growth is arrested.
Presence of insulin or IGF-1 stimulates the expression of AT2 receptor in vascular
smooth muscle cells in serum free conditions, whereas serum growth factors, like PDGF,
lysophospatidic acid and phorbol ester rapidly decreases AT2 receptor expression (109,
110). Insulin or IGF-1 mediated AT2R activation seems to be a slow process taking
several days. An insulin response sequence is located at -126 to -117 of the 5’-flanking
region of the rat AT2 receptor gene. (111). The effect of insulin on AT2 expression is
observed in the aorta of obese (fa/fa) Zucker rats which have about 10 times higher
plasma insulin concentrations than Sprague-Dawley rats and expresses AT2 mRNA at a
much higher levels than Sprague-Dawley rats (109).
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Figure 1.8:

1.1.6

Structure and the consensus sequence of the AT2 receptor

AT2 receptor signaling
Even though the AT2R belongs to the GPCR family of proteins, it does not show

all functional features attributed to this class of receptors such as coupling to the
heterotrimeric G proteins. The signaling mechanisms of the AT2 receptor are diverse, and
only a few of them have been characterized reasonably well. Nouet and Nahmias
suggested that AT2R can transduce signaling mechanisms by a) activation of various
protein phosphatases causing dephosphorylation b) activation of NO/cGMP system and
c) stimulation of phospholipase A2 and subsequent arachidonic acid release. Expression
of AT2R in the absence of AT1R does not induce changes in the cytosolic Ca2+ or cAMP
which are characteristic indicators of the heterotrimeric Gq protein coupled activation of
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PLCȕ or Gi/Gs coupled inhibition or activation of the adenylyl cyclase (103, 107, 112115). In some cases, AT2-Rs are coupled to GiĮ2- and GiĮ3- proteins (116, 117). AT2R
activates tyrosine phosphatases, Ser/Thr phosphatases and protein kinase phosphatases.
Activation of the tyrosine phosphatase SHP-1 occurs via the GȕȖ-independent
constitutive association of GĮS with SHP-1 and the AT2-R. It is known that the AT2
receptor can inhibit AT1R mediated Gq protein coupled phospholipase C activation (118120).
An AT2R coupled increase in NO generation could be observed in vascular tissue
of diverse origin. For example, in the vasculature, this signaling cascade may mediate
vasorelaxation, a common result of NO production, while in the kidney, it contributes to
natriuresis (121). The effect of AT2R on cGMP production is unclear and is tissue and
cell specific. Bottari et.al has shown in rat adrenal glomerulosa cells and Sumners et.al
has shown in neonatal neuronal cells that there is a decrease in cGMP levels brought
about by the reduction in soluble guanylyl cyclase and activation of phosphatases or by
the action of phosphodiesterases. (32,33) In a neuroblastoma cell line, NE115, AT2
increases cGMP levels through a mechanism that involves both AT1 and AT2 receptors
and NO mediated stimulation of guanylyl cyclase (103, 112, 114, 122-125). The effects
of Ang II on cellular cGMP content were abolished by pretreatment with the calcium
channel blockers cadmium and nifedipine, and by the nonselective phosphodiesterase
inhibitor 3-isobutyl-1-methylxanthine. These results suggested that calcium entry and
activation of a phosphodiesterase enzyme are involved in this Ang II-induced effect
(123). Pulakat et al. demonstrated the structural determinants involved in the ability of
the AT2 receptor to reduce cGMP levels in Xenopus oocytes upon activation by Ang II.
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The ability of three mutants of the AT2 receptor on AT2-mediated reduction of cGMP
was investigated. It was observed that the C-terminal cytoplasmic tail acts as a negative
regulator of this function. However, mutating the highly conserved DRY motif (D141GR142G-Y143A) of the 2nd ICL implicated in activating GiĮ subunit of trimeric Gproteins did not affect AT2-mediated cGMP reduction. In contrast, mutations T250RR251N and L255F-K256R located in the C-terminus of the 3rd ICL of AT2 abolished
AT2-mediated cGMP reduction in oocytes (124-127). Recent studies on the effect of the
AT2 receptor in kidney indicate that there is an increased renal medullary and cortical
interstitial cGMP level through a bradykinin mediated mechanism (128-130).
Another signaling pathway involves the activation of protein phosphotyrosine
phosphatases (PTPases), which are crucial to prevent or rapidly shut off undesired and
uncontrolled growth of normal tissues (42). Up to now, three specific phosphatases have
been identified, which are stimulated upon AT2R activation: mitogen-activated protein
kinase phosphatase 1 (MKP-1) (131), SH2 domain-containing phosphatase 1 (SHP-1) [5],
and protein phosphatase 2A (PP2A) (132). MKP-1 and SHP-1 are tyrosine phosphatases
and vanadate-sensitive. MKP-1 also dephosphorylates threonine-residues, while PP2A is
an okadaic acid-sensitive serine/threonine phosphatase (133). The AT2R is known to
have a negative cross talk with phosphorylation cascades via the phosphatases activity.
The most studied is the dephosphorylation of the ERK1/2 signaling cascade which could
be involved in the proapoptotic actions of the AT2 receptor.
More recently it has been shown that the AT2 receptor results in activation of
phospholipase A2. Activation of PLA2 increases arachidonic acid release leading to the
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activation of Na/HCO3 symporter which may be a unique regulatory mechanism that
regulates intracellular pH (134).
Nouet et al. demonstrated interaction of the C-terminal tail of the AT2 receptor
with a novel protein, ATIP1 (AT2-interacting protein). Ectopic expression of ATIP1 in
eukaryotic cells leads to inhibition of insulin, basic fibroblast growth factor, and
epidermal growth factor-induced ERK2 activation and DNA synthesis and attenuates
insulin receptor autophosphorylation, in the same way as the AT2 receptor. The ATIP
mediated inhibitory effect of does not require activation of the AT2 receptor by Ang II,
but is further increased in the presence of Ang II, indicating that ATIP1 cooperates with
AT2 to transinactivate receptor tyrosine kinases (135).
Unlike the AT1R, the AT2 receptor lacks the mechanism of rapid desensitization,
internalization, and low-affinity shift by GTP. Classical heterotrimeric G proteins bind to
a stable analog of GTP upon stimulation by agonist to their respective receptor. However,
stimulation of the AT2R did not result in an increase in the binding of the GTP analog
[35S]GTPȖS in membranes from human myometrium, bovine cerebellar cortex, and rat
adrenal glomerulosa (136). These results suggest a G protein independent mechanism for
the signaling of the AT2R.
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Figure 1.9: Signal transduction and physiological effects of AT2 receptor(137)

1.2

1.2.1

Insulin, Insulin receptor and signaling

History of insulin
Insulin and insulin like growth factors belong to a family of peptide hormones

that are important for the control of essential cellular and physiological processes such as
the cell cycle, survival or apoptosis, cell migration, proliferation and differentiation, and
body growth, metabolism, reproduction, and longevity. The successful isolation of insulin
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by Frederick Banting and Charle’s Best in 1921 was one of the most significant events
for the field of protein chemistry (138-140). Many of the findings of structure and
function of proteins were based on insulin as a model. Even after the isolation of insulin,
it took another six years to establish that insulin is a protein. It was only in 1955 that the
primary amino acid structure of insulin was elucidated by Fred Sanger (141). X-ray
crystallography studies by Dorothy Hodgkin made the three dimensional structure of
insulin available in 1969. Don Steiner elucidated the biosynthetic pathway of insulin
from the beta cells of the pancreas in 1967 (142). Insulin was also the first hormone to be
measured using radio immunoassay and the first protein to be biosynthesized in
microorganisms using recombinant biotechnology (143, 144).

1.2.2

Structure of insulin
The biologically active form of insulin is a monomer consisting of two chains, A

(21 amino acids) and B (30 amino acids), which are linked by two disulfide bridges. The
A chain contains an intrachain disulfide linkage between A7 and A11. At micromolar
concentrations, insulin dimerizes and in the presence of zinc ions associates to form
hexamers (Figure 1.10). The basic structure of insulin is conserved throughout evolution.
The insulin monomer has two extensive non polar surfaces which plays a role in the
formation of dimers and hexamers. The 2 zinc insulin hexamer can take a T form or an R
form depending on the crystallographic conformation of the A and B chains. In phenol
containing crystals all the monomers are in the R form (R6) (145-148). The surface
residues that are involved in receptor binding and biological activity were identified using
radioactive assays and were found be conserved during vertebrate evolution. These
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residues that are conserved during vertebrate evolution and referred to as the classical
binding surface are as follows- Gly A1, Gln A5, Tyr A19, Asn 21, Val B12, Tyr B16,
Gly B23, Phe B24, Phe B25, Tyr B26 (149). Mutagenesis studies demonstrated that
residues outside the classical binding surface such as LeuA13 and LeuB17 are also
important in receptor binding (150).

Figure 1.10:

The insulin hexamer
One monomer of each dimer is colored in light blue and the second
monomer in dark blue. The zinc is shown in yellow in the center
(148)

1.2.3 Biosynthesis of insulin
Insulin is secreted from the beta cells of the pancreas. Most species have only a
single insulin gene (151-153). The insulin mRNA is translated as a single chain precursor
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called preproinsulin. The signal peptide is removed during insertion into the endoplasmic
reticulum to produce proinsulin. Proinsulin has three domains- the carboxy terminus,
amino terminus and a connecting peptide known as the C peptide. Action of various
endopeptidases excises the C peptide giving rise to the A chain and B chain of insulin.
When the beta cell is stimulated by glucose or other factors like amino acids and fatty
acids, insulin is exocytosed from the beta cell into the islet cell capillary along with C
peptide. The hormone is secreted into the systemic circulation in pulses and has a t1/2 of
approximately 3 minutes with liver removing almost 50% of the insulin. This is known as
the first pass effect. The index of insulin secretion therefore is measured using the C
peptide levels which is released in a 1:1 ratio with insulin and has a t1/2 of 30 minutes.
The insulin that escapes the liver’s inactivating activity is responsible for the regulatory
actions on peripheral tissues.

1.2.4

Control of insulin secretion
Insulin is secreted into the blood in response to elevated glucose levels. The main

role of insulin is to facilitate the glucose uptake into cells for metabolism. Glucose is
transported into the beta cell by facilitative diffusion through a glucose transporter. The
elevated levels of glucose in the beta cell results in membrane depolarization with an
influx of calcium into the cell. The resulting increase in intracellular calcium results in
the exocytosis of insulin from the insulin secreting granules. Infusion of glucose results in
an immediate release of insulin into the blood due to this effect. This insulin is depleted
very soon and the secondary rise in the insulin levels is due to the glucose stimulated
transcription and translation of the insulin gene (154).
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1.2.5

Insulin receptor: Structure
The presence of a membrane receptor mediating the physiological effects of

insulin was postulated in 1949 by Rachmiel Levine (155). Radioligand binding assays
performed using monoiodinated insulin revealed a membrane receptor for insulin in rat
liver (156, 157). Insulin receptor (IR) belongs to the superfamily of receptor tyrosine
kinases (RTK) (158). Most of the RTKs such as insulin like growth factor 1 receptor,
fibroblast growth factor receptor, epidermal growth factor receptor , nerve growth factor
receptor etc are dependent on the phosphorylation of the tyrosine residues in the kinase
domain of the receptor for its activation and initiation of subsequent signaling (159). The
human insulin receptor gene is located on the short arm of chromosome 19 and spans
greater than 120kbp with 22 exons (160-162). IR is present in almost all tissues to
varying degrees of receptor concentration. Insulin receptor is a heterotetrameric
transmembrane glycoprotein with an intrinsic tyrosine kinase activity (163-165).
Radiolabeled insulin binding studies were performed for biochemical
characterization of the receptor in the early seventies. These studies in conjunction with
crystallography and mutational studies of IR demonstrated the structural functional
relationship of IR, specifically of the receptor tyrosine kinase domain. The subunit
structure of the IR was investigated in the early eighties and it was shown that it is made
of a covalent dimer of two alpha and two beta subunits that are linked to each other by
disulfide bonds (166). The structure of the IR appears to be highly conserved in
vertebrate and invertebrate cells (167, 168). The receptors are synthesized as single chain
preproreceptor that are processed, glycosylated, folded and dimerized to yield the mature
Į2ȕ2 receptor (Figure 1.11). The alpha subunit is located completely outside the cell with
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the insulin binding site whereas the beta subunit spans the membrane into the
intracellular region where the regulatory tyrosine kinase domain and the ATP binding site
is located (166). At least three domains have been identified as ligand binding sites using
photo affinity labeling. These include the L1 domain and an Į C-terminal peptide
sequence (amino acid 704-715). A third binding site which has not been mapped exists in
the C terminal part of L2 domain and the first fibronectin III domain (169). The
unoccupied alpha subunit of the IR which is released upon ligand binding inhibits the
tyrosine kinase activity. Insulin binding to the alpha subunit of the receptor induces
extensive tyrosine phosphorylation of the beta subunit and various protein substrates. At
least six tyrosine residues are phosphorylated including one in the juxtamembrane
domain (Y972), three in the kinase domain (Y1158, 1162 and 1163) and two in the
carboxy terminal of the receptor (Y1328 and 1324). Autophosphorylation of the three
tyrosine residues on the kinase domain is crucial as the unphosphorylated, low activity
form of the IR has an autoinhibitory mechanism (164, 165).
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Figure 1.11:

Į2ȕ2 structure of the insulin receptor.
On the left half of the receptor, spans of the 22 exon-encoded
sequences. On the right half, spans of predicted protein modules.
Orange arrowheads: N-glycosylation sites. Green arrowheads:
ligand-binding ‘‘hotspots’’. L1: large domain 1. CR: cystein-rich
domain. L2: large domain 2. Fn: fibronectin type III domains. TM:
transmembrane domain. JM: juxtamembrane domain. TK: tyrosine
kinase domain. CT: Cterminal domain. (169)

1.2.6

Important structural domains of the IR
x

Hydrophobic Signal peptide: Consists of 30 hydrophobic amino acids at the N
terminus of the proreceptor. The signal peptide is proteolytically cleaved co
translationally (170).
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x

N-terminal repeat domain: N terminal half consists of two large homologous
globular domains, L1 (1-120) and L2 (211-428), separated by a cysteine rich
region. This domain consists of four repeats of a loosely conserved motif. The
N terminal domain of the IR plays an important role in ligand binding. The
Cys-rich region is proposed to consist of a series of disulfide-linked modules
(171).

x

Juxtamembrane domain: The region of the beta subunit close to the plasma
membrane involved in docking of IRS-1-4, Shc, as well as in receptor
internalization. The binding of the two molecules to the tyrosine in the
juxtamembrane domain happens through phosphotyrosine binding
domain(172).

x

Tyrosine kinase domain: The intracellular portion of the beta subunit contains
the kinase domain. The tyrosine kinase domain appears to be a conserved
region in the RTKs such as IGFR and EGFR. This region has the ATP binding
domain involved in the protein kinase activity and the three tyrosine residues
in the activation loop. Vast majority of the RTKs contain between one and
three tyrosine residues in the kinase A loop(164, 165).

x

C terminal domain: Consists of three fibronectin III type of domains
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Figure 1.12:

1.2.7

Schematic illustration of two step process of receptor ligand
binding (169)

Insulin signaling pathway
Binding of insulin to the alpha subunit of the IR brings about a conformational

change in the alpha subunits which then changes the conformation of the beta subunit.
The change in the receptor conformation results in the activation of the intrinsic kinase
domain which then starts a series of phosphorylation and dephosphorylation cascade. The
altered conformation allows the ATP binding to the intracellular region of the beta
subunit and activates receptor autophosphorylation. The phosphorylated tyrosine residues
on the beta subunit are then recognized by the phosphotyrosine binding domain (PTB) of
the substrates like IRS. Receptor activation leads to the phosphorylation of key tyrosine
residues on IRS proteins, some of which are recognized by the Src homology 2 (SH2)
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domain of the p85 regulatory subunit of PI 3-kinase. The catalytic subunit of PI 3-kinase,
p110, then phosphorylates phosphatidylinositol (4, 5) bisphosphate (PtdIns(4,5)P2)
leading to the formation of Ptd(3,4,5)P3. PIP3 regulate three classes of molecules: the
AGC family of serine/threonine kinases, guanine nucleotide-exchange proteins of the
Rho family of GTPases and the TEC family of tyrosine kinases. A key downstream
effector of Ptd(3,4,5)P3 is Akt (or PKB), which is recruited to the plasma membrane.
Activation of Akt also requires the protein kinase 3-phosphoinositide-dependent protein
kinase-1 (PDK1), which in combination with an as yet unidentified kinase leads to the
phosphorylation of Akt. Once active, Akt then enters the cytoplasm where it leads to the
phosphorylation and inactivation of glycogen synthase kinase 3 (GSK3). A major
substrate of GSK3 is glycogen synthase, an enzyme that catalyses the final step in
glycogen synthesis. Phosphorylation of glycogen synthase by GSK3 inhibits glycogen
synthesis; therefore the inactivation of GSK3 by Akt promotes glucose storage as
glycogen.
In addition to PI(3)K activity, other signals seem to be required for insulinstimulated glucose uptake which involves tyrosine phosphorylation of the Cbl
protooncogene. In most insulin-responsive cells, Cbl is associated with the adapter
protein CAP, which binds to proline-rich sequences in Cbl through its carboxyl-terminal
SH3 domains. Upon phosphorylation, the Cbl–CAP complex translocates to lipid raft
domains in the plasma membrane. Expressions of dominant-interfering CAP mutants that
cannot bind to Cbl or flotillin inhibit Cbl translocation and insulin-stimulated glucose
uptake. Translocation of phosphorylated Cbl recruits the adapter protein CrkII to the lipid
raft via interaction of the SH2 domain of CrkII with phospho-Cbl. CrkII also forms a
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constitutive complex with the guanyl nucleotide-exchange protein C3G. Once
translocated into lipid rafts, C3G comes into proximity with the G protein TC10, and
catalyses the exchange of GTP for GDP, resulting in the activation of the protein. The
localization of TC10 in lipid rafts is required for its activation by insulin. Once activated,
TC10 seems to provide a second signal to the GLUT4 protein that functions in parallel
with the activation of the PI(3)K pathway. This may involve the stabilization of cortical
actin, which seems to be important in GLUT4 vesicle translocation to the plasma
membrane. .
As is the case for other growth factors, insulin stimulates the mitogen-activated
protein (MAP) kinase extracellular signal-regulated kinase (ERK). This pathway involves
the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the
adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the
plasma membrane for activation of Ras. The activation of Ras also requires stimulation of
the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as
Gab-1 or IRS1/2. Once activated, Ras operates as a molecular switch, stimulating a serine
kinase cascade through the stepwise activation of Raf, MEK and ERK. Activated ERK
can translocate into the nucleus, where it catalyses the phosphorylation of transcription
factors initiating a transcriptional program that leads to cellular proliferation or
differentiation.
Insulin increases synthesis and blocks the degradation of proteins through
activation of mTOR. mTOR can control the mammalian translation machinery by direct
phosphorylation and activation of p70 ribosomal S6 kinase as well as phosphorylation of
the initiation factor 4E for eukaryotic translation (eIF-4E) inhibitor, PHAS1 or 4E35

binding protein 1. P70rsk activates ribosome biosynthesis by phosphorylating the
ribosomal S6 protein. P70rsk also requires a second PtdIns(3,4,5)P3-dependent
phosphorylation, presumably catalysed by PDK1. Phosphorylation of PHAS-1 by mTOR
results in its dissociation from eIF-2, allowing cap-dependent translation of mRNAs with
a highly structured 5'-untranslated region (173-180).
Insulin acting via its insulin receptor thus helps in glucose uptake, regulation of
glycogen synthesis, inhibition of gluconeogenesis and regulates lipids synthesis and
degradation.

Fig 1.13:

Insulin signaling pathway (www.abcam.com)
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1.3

Crosstalk between insulin-renin angiotensin systems

The insulin signaling system and the RAS are known to play an important role in
the pathophysiology of insulin resistance and hypertension respectively. There is a large
amount of evidence suggesting a crosstalk at multiple levels between the signal
transduction pathways that mediate insulin and Ang II actions. The impaired insulin
sensitivity and signaling in essential hypertension could be due to hyperactivation of RAS
(181, 182). Recent clinical studies have shown a significant improvement in insulin
sensitivity with antihypertensive drugs like ACE inhibitors or ARBs. However, these
treatments also result in a number of unwanted side effects such as hyperkalemia,
angioedema, kidney failure and fetal death in pregnant women. Since Ang II is a
hormone implicated in a number of signaling pathways, it is important to know which of
the Ang II mediated pathways result in the development of insulin resistance. Thus, it is
of crucial interest to elucidate the metabolic pathways affected by the insulin-RAS
system crosstalk at different levels in order to find novel treatment approaches aimed at
blocking the progression and the clinical outcomes of the insulin resistance syndrome.
Hypertension or high blood pressure is determined by the amount of blood that
the heart pumps. The condition develops slowly over many years. There are two types of
high blood pressure- primary or essential hypertension and secondary hypertension. In
the case of primary hypertension, which affects 90 to 95% of high blood pressure
patients, there is no identifiable cause for the development of the disease which is a
gradual progression. However in the remaining 5-10% of cases with secondary high
blood pressure, the disease is due to an underlying condition. This appears suddenly and
causes higher blood pressure than essential hypertension. According to the American
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Heart Association, high blood pressure was listed as one of the major causes of death of
57,356 Americans in 2005. About 73.6 million people in the United States age 20 and
older have high blood pressure that accounts for one in three U.S. adults with high blood
pressure. In fact, many people have high blood pressure for years without knowing it.
Uncontrolled high blood pressure can lead to stroke, heart attack, heart failure or kidney
failure. This is why high blood pressure is often called the "silent killer." It is generally
agreed that risk of cardiovascular diseases is higher in patients with essential
hypertension. Hypertension is usually clustered with insulin resistance, dyslipidemia,
glucose intolerance and obesity (183). The occurrence of insulin resistance in essential
hypertension is very high, with ~ 50% of hypertensive patients being insulin resistant
(184). According to the American Diabetes Association there are 23.6 million people in
the United States, or 8% of the population, who have diabetes. The total prevalence of
diabetes increased 13.5% from 2005-2007. Insulin resistance is a condition when the
body cannot use insulin efficiently which predisposes the patient to the risk of a full
blown diabetes. Insulin resistance, like hypertension is an asymptomatic condition. The
body tries to compensate for the lack of insulin signaling and the glucose uptake by
producing more insulin from the pancreas. Gradually the insulin producing cells get
exhausted resulting in high blood glucose levels. Diabetes is one of the six major
controllable risk factors for cardiovascular disease. In fact, adults with diabetes are two to
four times more likely to have heart disease or a stroke than adults without diabetes.
Diabetic patients also have a higher propensity to develop structural and functional
abnormalities of the microvasculature, autonomic dysfunction and intrinsic failure of
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myocardial contraction, or the diabetic cardiomyopathy. These conditions are amplified
by hypertension coexisting with diabetes (185).
Essential hypertension is an insulin resistant condition in which early insulin
signaling steps are impaired (186-188). It is estimated that about 25–47% of individuals
with hypertension have insulin resistance or impaired glucose tolerance (189). With
insulin resistance there are impaired biological and physiological tissue responses to
insulin. The complex cellular interactions of the RAS and insulin signaling include the
shared signal transduction pathways, including the PI3 kinase and MAP kinase pathways.
Insulin receptor–mediated activation of IRS1 and IRS2 activates the PI3 kinase pathways,
whereas their Ang II-mediated activation inhibits PI3 kinase.
Ang II stimulates the tyrosine phosphorylation of IRS 1 and IRS 2 in rat heart and
in rat aortic smooth muscle cells. Ang II also induces a rapid phosphorylation of tyrosine
residues in Jak 2, a member of janus kinase family that increases its catalytic activity and
induces its association and co-immunoprecipitation with IRS 1 and IRS 2.
The rapid tyrosine phosphorylation and association of Jak 2 with IRS 1 and IRS 2 suggest
that a large signaling complex is formed with the AT1R upon Ang II treatment. There are
3 hypothetical mechanisms by which Jak 2 and IRSs may associate with AT1R. Jak2 is
initially associated with the AT1R which recruits IRSs proteins and they bind Jak2. JAK2
and IRSs are associated with AT1 and Jak 2 phosphorylates IRSs when the ligand binds
to the receptor. After the tyrosine phosphorylation of IRS 1 and IRS 2, these proteins
dock to the p85 subunit of PI 3 kinase and its activity is inhibited by angiotensin II in a
dose dependent manner.
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In vivo and cell culture studies demonstrate that Ang II inhibits insulin signaling
via the PI3 kinase pathway both in the basal and insulin stimulated states, without
affecting tyrosine phosphorylation of IRS I and of the insulin receptor beta subunit.
Additionally, AT1 receptor antagonists could block these latter phenomena.
The studies to understand the mechanism by which Ang II influences insulin signaling
have shown that Ang II negatively modulates insulin signaling by stimulating multiple
serine phosphorylation events in the early components of the insulin signaling cascade
the insulin receptor itself, IRS 1 and the p85 subunit of P13 kinase. The serine
phosphorylation of IRS 1 blunts its ability to dock the tyrosine phosphorylated beta
subunit of the insulin receptor.
One of the mechanisms by which Jak/STAT transduces its signaling mechanism
is by the expression of suppressor of cytokine signaling (SOCS). SOCS proteins are
expressed independently by Ang II and insulin signaling pathway. In certain tissues and
some mammalian cell lines, Ang II and insulin are the lone inducers of SOCS. Depending
on the tissue/cell type, insulin can activate SOCS2 and/or SOCS3. SOCS3 can bind to
Tyr960 of the IR and negatively modulate its ability to phosphorylate IRS 1 and IRS 2. In
addition, insulin induced SOCS3 can also bind to the IRS 1 and result in its proteosomal
degradation. In heart and cardiomyocytes, Ang II can activate the expression of SOCS3
via Jak 2. The Ang II induced SOCS3 not only interact with the Ang II signaling, but also
with the insulin signaling. At the molecular level, they inhibit insulin induced tyrosine
phosphorylation of IRS I and IRS 2 and Ser473 phosphorylation of Akt. In addition, they
impair the transduction of the insulin signal through the Jak2/STAT-5b pathway. At the
functional level, Ang II-induced SOCS3 partially inhibits insulin-induced GLUT 4
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translocation from its intracellular pool to the membrane. Thus, it is clear that SOCS 3
provides a distal interface between the Ang II and insulin signaling systems.
There are reports suggesting that both hyperglycemia and hyperinsulinemia
activate the RAS by increasing the expression of Ang II, and the AT1 receptor, which, in
concert, may contribute to the development of hypertension in patients with insulin
resistance (70, 190). Ang II acting via AT1 receptors is a powerful stimulus for the
generation of ROS in the blood vessels from the NAD(P)H oxidases (75), which become
further upregulated in hyperglycemic states (191). An increased oxidant stress is
instrumental in provoking endothelial dysfunction, inflammation, smooth muscle
hypertrophy, and vascular remodeling. RAS-driven oxidative stress also has been
proposed as a stimulus for the formation of advanced glycation end products. Advanced
glycation end products are compounds formed by nonenzymatic glycation of amino acids
on proteins, lipids, and nucleic acid. ROS act on a cell surface receptor for advanced
glycation end products and play a key role in the pathogenesis of vascular injury in
hyperglycemic states mediated in part by NAD(P)H dependent generation of ROS. In
experimental studies, inhibition of the RAS with ACE inhibitors and ARBs is associated
with a reduced formation and accumulation of advanced glycation end products (192,
193). Further proof for the crosstalk comes from the widely known metabolic effects of
antihypertensive drugs on glucose metabolism and insulin sensitivity.

1.4

Dissertation Statement/Aim of the Investigation

The overall objective of the work reported in this dissertation is to understand the
cross talk between insulin and Ang II and also to evaluate the effect of Ang II in the
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development of insulin resistance using molecular and cellular techniques. This effort
seeks to answer the question of whether there is a receptor level association occurring
between the Ang II receptors and the IR and how this association affects the downstream
insulin mediated signaling pathways. Also, we proposed to understand the domain of the
IR involved in these interactions. To understand the regions of IR involved in this
mechanism, we utilized the yeast two-hybrid system and to evaluate the receptor level
association, we performed immunoprecipitation analysis. The effect of Ang II in
orchestrating the transcriptional changes on an insulin responsive organ like heart was
studied using exon array techniques. The results were substantiated by comparison with
available experimental data from the literature.
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CHAPTER II
ANGIOTENSIN II RECEPTOR AT2-INSULIN RECEPTOR IR ASSOCIATION:
ROLE IN ANGIOTENSIN II MEDIATED MODULATION OF IR SIGNALING

2.1

Introduction

Angiotensin II (Ang II) is a well-characterized pressor hormone. It is responsible
for the induction of vasoconstriction and hypertension via activation of the AT1 receptor.
In contrast, activation of the second Ang II receptor AT2 results in inhibition of many of
the AT1-mediated effects. For example AT2 is a vasodilator and reduces blood pressure,
causes natriuresis, and inhibits cell growth. This ability of AT2 to oppose AT1-mediated
signaling has resulted in the suggestion that AT2 expression has a protective role in
patho-physiological conditions. This is further supported by a recent study that shows
AT2 receptor stimulation could contribute to the inhibition of pheochromocytoma
progression (1).
An interesting aspect of the AT2 is its transient expression pattern during
embryonic development, wound healing and in some patho-physiological conditions (28). For example, transient, high level expression of the AT2 is seen in epithelial cells
such as ovarian follicular cells during atresia. AT2-mediated phosphatase activation (such
as SHP-1) has been implicated in AT2-mediated inhibition of cell growth via termination
of signaling by cytokine- and growth factor-receptors (9) (10). However, Elbaz et al.,
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have shown that AT2 -mediated functional trans-inactivation of insulin receptor kinase in
Chinese Hamster Ovary cells (CHO) stably expressing human AT2 was not due to AT2mediated activation of vanadate-sensitive tyrosine phosphatases (11). The study used
other cell systems that express endogenous AT2 (such as neuroblastoma NIE115 cells,
and pancreatic acinar AR42J cells) and showed similar AT2-mediated inhibition of IRbeta tyrosine phosphorylation. It was observed that AT2 could inhibit the IRautophosphorylation in response to insulin binding. This effect was insensitive to
pertussis toxin suggesting the lack of involvement of Gi/Go-proteins. This study also
ruled out involvement of serine/threonine phosphorylation of the IRȕҏ by protein kinase C.
The consequence of this AT2-mediated inhibition of phosphorylation of the IRȕҏ was lack
of tyrosine phosphorylation of insulin receptor substrate 1 (IRS 1) and signal-regulatory
protein (SIRPĮ1) and lack of association of both IRS 1 and SIRPĮ1 with Src homology 2
(SH2)-containing tyrosine phosphatase SHP-2. Based on these observations it was
proposed that a novel, as yet unexplained, phosphatase-independent mechanism is
involved in the AT2-mediated inhibition of phosphorylation of IRȕ.
The AT2 receptor is structurally similar to the AT1 receptor: both have 7transmembrane domain (7-TMD) topology (12). They share 34% amino acid identity; the
least similarity is observed between their 3rd intracellular loops (ICLs). The AT1 is
implicated in the pathogenesis of type II diabetes and some of the underlying signaling
mechanisms are characterized (13). The AT1 antagonists such as losartan (DUP753),
candesartan and telmisartan are all capable of reducing insulin resistance in patients with
hypertension. Similar results have been obtained in studies with spontaneously
hypertensive rats and in mice models with type 2 diabetes. It was shown that cross-talk
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between the Ang II and insulin signaling systems is multifaceted in heart tissue and
cardiac myocytes; within minutes of Ang II exposure, Ang II acting via Janus kinase 2
(Jak2) tyrosine-phosphorylates insulin receptor substrates (IRSs), and inhibits
phosphatidylinositol 3-kinase (PI-3 kinase) activity (14). In addition, Ang II also causes
serine phosphorylation of IR and IRS (15). Finally, Ang II induces expression of a
regulatory protein SOCS3 that controls IR signaling. Ang II and its receptors are also
involved in the functions of normal and cancerous breast tissue. In breast cancer cell line
MCF-7 that express the AT1 when grown in complete medium (minimum essential
medium supplemented with 10% FBS), a 2-hour exposure to Ang II resulted in a timedependent AT1-IRȕ complex formation that paralleled AT1-mediated inhibition of
insulin binding to IR. Both AT1-IRȕ complex formation and AT1-mediated inhibition of
insulin binding to IR could be inhibited by the AT1-antagonist Losartan. These
observations suggested a novel mechanism for AT1-mediated regulation of IR signaling
in breast cancer cells that involves complex formation of the AT1 receptor with the beta
subunit of IR.
Based on the observation that the AT1 could associate with IR, we hypothesized
that the AT2 could also associate with IR and such association could play a role in AT2mediated and phosphatase-independent inhibition of IRȕ phosphorylation observed in
CHO cells. Previously we have shown that the AT2 interacts with the ATP-binding
domain of the receptor tyrosine kinase ErbB3 and the 3rd ICL and C-terminal cytoplasmic
domain of the AT2 are involved in this interaction (16). This observation prompted us to
posit that AT2R would interact with IR (which is also an RTK) via the same intracellular
regions. Therefore, we expressed rat AT2 receptor (wild type) and a truncated AT2 (in
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which the C-terminal cytoplasmic domain was truncated by introducing a stop codon at
position 332) in CHO cells and analyzed whether or not these receptors associated with
IRȕ and inhibited insulin-induced tyrosine phosphorylation. To further elucidate the
structural domains involved in the IR-AT2 association, a yeast two-hybrid assay was
performed using various mutants of the AT2R and different subclones of the IR. In
addition, we determined effects of inducing transient endogenous AT2 expression on IRȕ
tyrosine phosphorylation in human breast cancer cell line MCF-7. Here we report that
AT2-IRȕ association occurs in epithelial cells in a parallel manner to AT2-mediated
inhibition of tyrosine phosphorylation of IRȕѽ, and 3rd ICL and C-terminus of the AT2 are
required for these orthovanadate-independent effects.

2.2

Materials and methods

2.2.1 Materials
The Chinese Hamster Ovary (CHO) cells and MCF-7 cells were from American
Type Culture Collection (ATCC). Human Angiotensin II, AT2-inhibitor PD123319,
Pertussis toxin (PTX), and Insulin were from Sigma Inc. (St. Louis, MO, USA). All
primary antibodies and agarose-conjugated antibodies were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA) and the ECL Western Blot kit was from Amersham
Biosciences. Bio-Rad DC Protein Assay kit was from BioRad laboratories. Hercules, CA.
Restriction enzymes and ligase were purchased either from Boehringer Mannheim
(Indianapolis, IN) or from Promega (Madison, WI). Oligonucleotides used for PCR
amplification were purchased from Integrated DNA Technologies (Coralville, IA).
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2.2.2

Cell Culturing, transfection, and exposure to ligands
The CHO cells were grown in 90% F-12 medium supplemented with 10% fetal

bovine serum (FBS) (both from ATCC) at 37oC in a 5% CO2 incubator. The MCF-7 cells
were grown in 90% Minimum Essential Medium (MEM) supplemented with 2mM Lglutamine, 1.5 g/L sodium bicarbonate, 0.1mM non-essential amino acids and 1mM
sodium pyruvate and 10% FBS (from ATCC) at 37oC in a 5% CO2 incubator. MCF-7
cells constitutively express AT1 receptor. However, we have seen that serum starving
these cells for 6 hours result in a change of expression pattern in the Ang II receptors.
Serum-starved cells show an increase in the levels of the AT2 receptor and a decrease in
the AT1 receptor level. To induce AT2 expression in MCF-7, the cells were allowed to
reach 90% confluency, complete medium was removed and cells were washed with PBS
and maintained in serum-free medium for 6hours. The cells were treated with 100nM
Ang II for 2 hours. In cells treated with PTX (400ng/mL), the treatment was initiated
with starvation. The cells were exposed to 1ȝM insulin 10 minutes prior to harvesting the
cells in all conditions.
Construction of pCDNA 3.1 derivative carrying rat C-terminal-deleted AT2 (in
which a stop codon is introduced at position 332) was reported previously. Transient
transfections were performed using Lipofectamine 2000 in 24 well plates and according
to the instructions of the manufacturer. For ligand exposure, the cells were washed with
PBS and then exposed to 100nM Ang II or 100nM Ang II+ 1ȝM PD123319 respectively
in serum-free medium for 2 hours.
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2.2.3

Immunoprecipitation and western blotting
The cells were lysed in nonidet lysis buffer [1% Nonidet P-40, 100mM NaCl,

75mM Tris–HCl pH 7.4, 50mM NaF, 3mM EDTA, and 1% protease inhibitor cocktail
(containing 34.84mg/ml PMSF, 1mg/ml aprotinin, 1mg/ml pepstatin in ethanol)]. This
lysis allowed membrane proteins to become soluble and the cell debris was removed by
quick centrifugation at 2500 rpm (1000×g) for 30 seconds. The protein concentrations
were measured using the Bio-Rad DC assay kit. The protein concentrations in all the
lysates were adjusted to the same level by dilution. The lysates were divided into two
parts, one for determining the levels of ȕ-actin and insulin receptor by immunoblotting
with appropriate antibodies and the other half for immunoprecipitation. For
immunoprecipitation, the lysates were pre-cleared by incubation with 10μL of agarose
protein G plus (0.5mL agarose/2mL) for 30 minutes on ice. The lysates were subjected to
centrifugation at 2500 rpm (1000×g) for 3 minutes and the supernatant was incubated
with 10 ȝL of agarose conjugated anti rabbit anti IRȕ antibody (500ȝg/0.25mL of agarose
in 1mL) for 4-6 hours on a rocker at 40C. The lysates incubated with agarose protein G
plus served as a negative control. Immunoprecipitated proteins were separated on 10%
SDS polyacrylamide gel and subjected to immunoblotting with goat anti-AT2 antibody to
test whether or not the AT2 could co-precipitate with IR-beta subunit. To identify the
tyrosine phosphorylation pattern of the ȕ subunit of the insulin receptor, the nitrocellulose
membrane was immunoblotted with mouse anti-phosphotyrosine antibody. The rainbow
marker was also loaded in one of the lanes of the SDS-PAGE gels used for separation of
the proteins to identify the molecular weights of the bands visualized by anti-AT2
antibody. ECL Western Blotting Analysis System (Amersham Biosciences) was used to
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visualize the presence of the AT2 or IR in the immunoblots generated, according to
manufacturer’s instructions. To determine the protein concentrations of AT2 or ȕ-actin in
MCF-7 cells, cell lysates were separated by SDS-PAGE, and subjected to
immunoblotting with anti-AT2 antibody or anti- ȕ-actin antibody. The NIH Image Scan
(Image J) program was used to quantify the intensity of the bands present on the
autoradiogram that were made visible by probing with the anti-AT2 or antiphosphotyrosine antibodies. The graphical representation of the quantification is
represented as percentage change in comparison to the control samples with the control
samples taken as 100%.
2.2.4

Yeast two-hybrid vectors and assay
The yeast two-hybrid vectors pGBKT7 and pGAD424 were obtained from

ClonTech. The yeast two-hybrid vector pGBKT7 derivatives used in this study were
pBG1101 in which the truncated AT2 (AT2226–363) is fused to GAL4 BD, pBG885 that
carries translational fusion of the GAL4 BD and the AT1:AT2 chimeric receptor,
pBG886 that carries translational fusion of GAL4 BD and AT2 mutant with Asp141GlyArg142Gly-Tyr143Ala amino acid changes (located in the 2nd ICL) and pBG5003 that
carries a stop codon at position 332 that resulted in deletion of 31 amino acids in the Cterminal cytoplasmic domain (Figure 2.1). Construction of these vectors was described
previously (3,4). The strategy for constructing a fusion protein in which the yeast GAL4
activation domain (GAL4 AD) or GAL4 binding domain fused to IR is as follows: The
plasmid pUC12 carrying the human IR gene was purchased from ATCC (pHIR/p12-1).
To construct translational fusion of the subunits of the IR and Gal4 AD, DNA fragments
encoding regions of IRĮ corresponding to amino acids 295 to 400 and the second
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fragment corresponding to amino acids 350-735 were PCR amplified using appropriate
primers listed in Table 2.1. Similarly, to obtain the cytoplasmic domain of the beta
subunit, DNA fragments encoding the regions corresponding to amino acids 1-620 252620 were PCR amplified separately. The primers used for generating these constructs are
given in table 2.1.
PCR amplification conditions were as follows: denaturing at 94ƕC, annealing at
55ƕC, and synthesis at 72ƕC. The DNA fragments were cloned into the pCR2.1 vector
(Invitrogen Inc.) originally. The pCR2.1 vector has a single 3’T overhang and a
topoisomerase covalently bound to the vector. The PCR product with a single 3’deoxy
adenine overhang will insert into the vector very efficiently due to the 3’T overhang. To
generate a translational fusion of GAL4 AD /GAL4BD and specific regions of the IR, the
DNA fragments carrying the IR were isolated from the pCR2.1 vector by restriction
digestion and were subcloned into the yeast two-hybrid vector pGAD424 or pGBKT7.
The vectors were subjected to restriction digestion with PstI and BamH1 for the first
fragment of IRĮ, EcoR1 and PstI for the second fragment of IRĮ; and EcoR1 and BamH1
for the IRȕ fragments and were ligated to the purified fragments using T4 DNA ligase.
Ligation was carried out overnight in a 160C water bath. The ligation mixtures were then
used to transform E. coli HB101 and the colonies were selected on 2YT plates
supplemented with ampicillin (parental vector pGAD424 carries the bla gene for
ampicillin resistance).
The growth conditions for E. coli strain HB101 and S. cerevisiae strains CG1945,
and Y190 were described previously [16]. The ampicillin was used at a final
concentration of 50 ȝg/ml and kanamycin was used to a final concentration of 25 ȝg/ml
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wherever the selection was made for the yeast two-hybrid vectors derived from
pGAD424 and pGBKT-7 respectively in E. coli. The transformation of S. cerevisiae
strains CG1945 or Y190 with the bait and prey plasmids, and analysis of interaction
between AT2 peptides and IRȕ by yeast two-hybrid assay were carried out using methods
described previously [16].
In the yeast two-hybrid system, GAL promoter present on the chromosome of the
yeast strain is fused to lacZ and his3 genes. If proteins encoded by the bait and prey
plasmid interact, it will result in bringing the binding domain and activation domain of
the transcriptional activator of Gal4 in close proximity and activation of the GAL
promoter. This can be detected by the ability of the strain to grow on His- SD plates and
by measuring the ȕ galactosidase activity of the transformed yeast strain. The positive
control used in these experiments was a yeast strain carrying the plasmids pVA3-1 and
pTD-1. pVA-3 encodes a fusion protein in which murine p53 has been fused to the Gal4
BD and pTD-1 encodes a fusion protein in which SV40 large T antigen is fused to the
Gal4 AD. The negative control used was a yeast strain carrying the plasmids pTD-1 and
pLAM5’-1 that encodes a fusion protein in which human lamin C is fused to the Gal4
BD.
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pBG885 (Chimera) - 3rd ICL of AT2
was replaced with that of AT1

pBG886 (Mutated) - Amino acids
Asp141-Arg142-Tyrosine143 was
replaced Gly141-Gly142-Ala143

pBG5003- C-terminal of the AT2 was
deleted by generating a stop codon
at 322

Figure 2.1:

pBG1101 (Truncated)- Amino
acids spanning from 226-363

AT2 receptor mutants used for the yeast two-hybrid assay. (3, 4)
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Table 2.1: List of oligonucleotide primers used for PCR amplification of specific
regions of IR
Forward primer used for generating

GAA TTC AGC AAC TTG CTG TGC ACC CCA TCC CTG GGT

the IRD fragment spanning the
amino acids 295-400
Reverse primer used for generating

CTG CAG AAG GAG TAG TTC CCA ATT TCC AAG GTC TC

the IRD fragment spanning the amino
acids 295-400
Forward primer used for generating

GAA TTC CTG GCA GCT GAG CTA GAA GCC AAC CTC

the IRD fragment spanning the amino

GGC

acids 350-735
Reverse primer used for generating

CTG CAG CTG CGT TTC CGA GAT GGC CTA GGG TCC TC

the IRD fragment spanning the
amino acids 350-735
Forward primer used for generating

GAA TTC TCC CTT GGC GAT GTT GGG AAT GTG ACG GT

the IRE fragment spanning the amino
acids 1-620
Reverse primer used for generating

GGA TCC TTA GGA AGG ATT GGA CCG AGG CAA GGT

the IRE fragment spanning the amino

CAG

acid 1-620
Forward primer used for generating

GAA TTC GAG GTG TCT CGA GAG AGA AGA TCA CCC

the IRE fragment spanning the amino

TCC

acids 252-620
Reverse primer used for generating

GGA TCC TTA GGA AGG ATT GGA CCG AGG CAA GGT

the IRE fragment spanning the amino

CAG

acids 252-620
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2.3

Results

Previously in our lab, it was shown that transient transfection of CHO cells with
rat AT2R resulted in IR-AT2 complex formation and that this association inhibited the
phosphorylation of the IRȕ subunit. However, the nature of the complex formation was
unclear. To obtain further insight into this phenomenon, experiments were performed to
determine whether or not AT2 interacted with IR in a similar manner to its interaction
with ErbB3 using Yeast-two hybrid assay. The effect of exposure to orthovanadate and
pertussis toxin on AT2-mediated modulation of IR signaling was also analyzed in
epithelial cells that express the AT2R.
2.3.1

Co-immunoprecipitation of the AT2 receptor with IRȕ
Previous studies from our lab had shown an interaction between the AT2 receptor

and ErBB3 receptors. Since ErbB3 and IR (both RTK) share similarities in the tyrosine
kinase domain and the ATP binding domain, we checked for AT2 interaction with IR in
serum starved MCF-7 cells.
As shown in figure 2.2, we observed a 45kDa band when these cell lysates were
immunoprecipitated using agarose conjugated IRȕ antibody. NIH Image J analysis was
performed to determine the intensity of the bands. A graph representing the differences in
the intensities of the bands at ~ 45kDa is shown in figure 2.2. There was at least 2-3 fold
increase in the band intensity for the immunoprecipitated samples in the serum starved
cells compared to the cells maintained in complete medium. There was no significant
difference in the beta actin or IR expression levels as was seen from the western blot
analysis of the tissue lysates.
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+Ang II
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+Ang II

Starved
+ PTX

IR
95kDa

Figure 2.2:

E actin
45kDa

AT2 association with IRȕ in MCF-7 cells.
Immunoprecipitation of IRȕ using rabbit anti IRȕ antibody and
probed with anti AT2 antibody. Protein level comparison between
the various samples for IR and ȕ actin is given in the
autoradiograms shown below the graph. At least three different
individual experiments were carried out for each of the treatments
and the data shown here is a representation of the results. The
percentage increase in the amount of AT2 that co-precipitated in
serum starved cells was approximately 2- 3 fold more than the
untreated cells maintained in serum. All the quantification was
performed using the NIH image J scan analysis. The percentage
change was calculated using control as 100%. Statistical
significance was calculated using Students T-test, p <0.05

These results suggest that there is a receptor level cross talk between the Ang II
receptor AT2 and the insulin receptor. Even in the absence of Ang II the amount of
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AT2R that co-precipitated with IR is the same as the Ang II treated cells under serum
starved conditions. Therefore it could be assumed that this effect is ligand-insensitive.
2.3.2

AT2 receptor expression inhibits tyrosine phosphorylation of the IRȕ subunit in

epithelial cells
Both stable transfection of human AT2R and transient transfection of the AT2R in
CHO cells result in inhibition of IR phosphorylation. To evaluate the effect of AT2R
association with IR signaling, we looked at the phosphorylation pattern of the IRȕ
subunit using an anti-phosphotyrosine antibody. The association between the two
receptors results in a reduction in the phosphorylation of the IR as is shown in figure 2.3.
However an interesting observation was the effect of PTX on the phosphorylation of IR.
The AT2 association with the IR was not affected by PTX; but the inhibition of
phosphorylation was partially reversed in PTX treated cells suggesting that this
mechanism has a PTX sensitive and insensitive component. NIH Image J analysis was
performed to determine the intensity of the bands is shown in figure 2.3.
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Figure 2.3:

Starved Starved
Ved +Ang II
+Ang II

Starved
+ PTX

Inhibition of IRȕ tyrosine phosphorylation (Yp) in MCF-7 cells
expressing AT2R.
Graphs represent the percentage changes (control taken as 100%)
of the area under the peak calculated using Image J. p<0.05 for the
change in association in serum starved cells in the absence and
presence of the ligand.

Our analysis provides further evidence that AT2R regulates IR signaling by
association with the IR and inhibits phosphorylation of the IRȕ subunit in serum starved
conditions. The AT2R expression is increased under conditions like ischemia. Blood
supply to the heart is reduced in ischemic conditions. An increased expression of the
AT2R in such conditions could lead to altered metabolic signaling and eventually tissue
damage due to lack of nutrients to the organ.
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2.3.3

AT2-IR association is insensitive to sodium orthovanadate:
AT2R signaling results in the activation of many Ser/Thr and Tyr phosphatases.

Elbaz et.al had shown in CHO cells that AT2 mediated inhibition of the IR
phosphorylation is an orthovandate insensitive mechanism (11). We investigated the
effect of orthovanadate on AT2-IR association to determine whether the treatment with
this phosphotyrosine phosphatase inhibitor will affect the association of the two
receptors. Sodium orthovanadate did not appear to affect the association in these
conditions (Figure 2.4). Thus, it can be concluded that the mechanism for the interaction
between the two receptors is not tyrosine phosphatase mediated. However, treatment with
the AT2R antagonist, PD123319, completely abolished the association between the two
receptors. Results obtained in our experiment are given in figure 2.4.
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Unstarved

UnstarStarved
Ved +Ang II

Starved
+Ang II

Starved
+ OV

Starved
+ PD

Starved
+ PD+Ang II

Effect of sodium orthovanadate on AT2-IR association.
There was no statistical difference in the amount of AT2 that coprecipitated with the IR in the starved cells and the starved cells
treated with orthovanadate (OV). The extent of AT2 coprecipitated with IR in serum starved cells treated with PD123319
(PD) was significantly lower suggesting that AT2 inhibitor could
inhibit AT2-IR association. All the quantification was done using
Image J analysis and the percent change was calculated using
control as 100%.

2.3.4

Cloning of the IR fragments and yeast two-hybrid assay
In an attempt to identify the specific domains of the IR involved in its interaction

with the AT2 receptor, we tested the ability of the various sub fragments of the alpha and
beta subunits to interact with the different AT2 receptor mutants given in figure 2.1. The
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different constructs that were made are given in table 2.2. Derivatives of the yeast strain
Y190 carrying different combinations of the ‘bait’ plasmids and ‘prey’ plasmids were
tested for their ability to grow on His- SD plates and also to express ȕ galactosidase
activity. Table 2.3 summarizes the result of growth on the His- SD plates and the liquid ȕ
galactosidase activity assays of the strains carrying these different plasmid combinations.
Our experiments with yeast two hybrid assays suggest that there is an interaction between
the AT2 receptor and IR. Truncated AT2 (pBG1101) shows the maximum interaction
with the beta subunit of the IR. The chimera (pBG885) and the DRY mutant show an
interaction with the beta subunit, but to a lower extent. These results support the data that
there is a physical interaction between the two proteins. No interaction was observed
between C-terminal deleted AT2 that lacked the 3rd ICL and the cytoplasmic tail,
suggesting that these that these regions may be involved in the association of the two
proteins. Figure 2.5 shows a typical filter lift assay with these strains using X-gal as
substrate for determining the ȕ galactosidase activity. From these results, we know that
the interaction between the two receptors is highly specific and the beta subunit of the IR
and the third intracellular loop and C-terminus domain of the AT2 receptor is essential
for this interaction to occur. The maximum interaction was observed between the IRȕ
subunit and a truncated AT2 peptide that contains the amino acids spanning from 262363. The interaction was abolished when the AT2 receptor mutant with the C terminal
deletion was used. The AT2 receptor with the third intracellular loop mutation showed a
slight reduction in the interaction, but the interaction was not completely absent.
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Table 2.2: List of the various IR fragments cloned into pGAD424/pGBKT7.

Construct Number

Description

pMSU5501

IRȕ full length in pGAD424

pMSU5502

IRȕ full length in pGBKT7

pMSU5503

IRȕ cytoplasmic in pGAD424

pMSU5504

IRȕ cytoplasmic in pGBKT7

pMSU5505

IRĮ 295-400 in pGAD424

pMSU5506

IRĮ 295-400 in pGGBKT7

pMSU5507

IRĮ 305-735 in pGAD424

pMSU5508

IRĮ 305-735 in pGBKT7

Table 2.3: Y2H: Growth on His- plates and liquid ȕ-galactosidase results
Plasmid 1: Gal4 BD
translationally fused to
pVA3-1 (Gal4 BD: p53)
pBG885 (Gal4 BD: AT2)
pBG886 (Gal4 BD: AT2)
pBG1101 (Gal4 BD: AT2)
pBG5003 (Gal4 BD: AT2)

Plasmid 2: Gal4 AD
translationally fused to

ß-galactosidase activity

pTD-1 (Gal4 AD: SV40 T antigen)
pMSU5501(Gal4 AD: IRß)
pMSU5501 (Gal4 AD: IRß)
pMSU5501 (Gal4 AD: IRß)
pMSU5501 (Gal4 AD: IRß)

++++
+++
++
+++
-
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Growth on
SD T – L – plates
++++++
++++++
++++++
++++++
++++++

Growth on
SD His- plate
++++
+++
++
+++
+

2
f

g
3

1

e
a

4

d

6
b

5
1-pVA3-1(Gal4 BD: p53)+pTD-1(Gal4 AD: SV40 T antigen)
2-pBG885(Gal4 BD: AT2)+pMSU5501(Gal4 AD: IRß)
3-pBG886(Gal4 BD: AT2)+pMSU5501(Gal4 AD: IRß)
4-pLAM (Gal4 BD: laminC)+ pTD-1(Gal4 AD: SV40 T antigen)
5-pBG5003(Gal4 BD: AT2)+ pMSU5501(Gal4 AD: IRß)
6-pBG5003(Gal4 BD: AT2)+pGAD424

Figure 2.5:

c

a-pVA3-1(Gal4 BD: p53)+pTD-1(Gal4 AD: SV40 T antigen)
b-pBG1101(Gal4 BD: AT2)+pMSU5501(Gal4 AD: IRß)
c-pBG856(Gal4 BD: AT2)+pMSU5501(Gal4 AD: IRß)
d-pGBKT7+pMSU5501(Gal4 AD: IRß)
e-pLAM (Gal4 BD: laminC+ pTD-1(Gal4 AD: SV40 T antigen)
f- pBG1153(Gal4 BD: AT1)+ pMSU5501(Gal4 AD: IRß)
6- pBG886(Gal4 BD: AT2)+pGAD424

Y2H: Filter lift assay.
Specificity of the interaction between the fusion protein
IRȕ:pGAD and the various mutants of the AT2 receptor. In these
experiments, the yeast strain Y190 cells carrying the different
plasmids were grown on SD Trp-Leu- plates and were transferred
to Whatman filters. The filters carrying the cells were then placed
over filters soaked with Z-buffer/Xgal solution according to the
protocols of MATCHMAKERTM yeast two-hybrid assay. The
truncated AT2 receptor showed activity comparable to the positive
control. An interaction is observed in the samples containing IRȕ
in combination with AT1-AT2 chimera, DRY mutant and the AT1
receptor. There was no interaction between the AT2 receptor in
which the C-terminal was deleted and IR.

2.3.5

Transient transfection of the C-terminal deleted mutant of AT2R in CHO

cells
To analyze the phosphorylation pattern of the IRȕ subunit in the absence of
association with the C-terminal deleted mutant of the AT2R, we transiently expressed the
C-terminal mutant in Chinese Hamster Ovary cells that lack the expression of Ang II
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receptors. The immunoprecipitation results showed similar result as was seen in Y2H
assay. As was expected, the lack of association did not affect the phosphorylation pattern
of IRȕ. This confirms that the C-terminal region of the AT2 receptor is crucial for the
association and inhibition of phosphorylation.

CHO CHO AT2 AT2
Ang
Ang

CD

CD
Ang

% change in Yp

140
120

IP: IRß
IB: Phosphotyrosine

100
80
60
40
20
0

Figure 2.6:

CHO

CHO
Ang

AT2

AT2
Ang

CD

CD
Ang

Autoradiogram and corresponding graph showing the reversal of
inhibition of phosphorylation by C-terminal deleted mutant (CD)
in CHO cells transiently transfected with the wild type and mutated
receptor.
Inhibition of IRȕ tyrosine phosphorylation by the AT2R was
reversed when the C-terminal deleted mutant was used for
transfections. Graphs represent the percentage change in tyrosine
phosphorylation calculated using the area under the peak in Image
J analysis. p<0.05
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2.4

Discussion

Many lines of evidence indicate that the AT2 receptor trans-inactivates IR by
inhibition of tyrosine phosphorylation of IR. Because tyrosine phosphorylation of IR is
essential for IR-signaling, such inhibition of phosphorylation of IR would prevent all
down-stream signaling by IR. Significance of such inhibition of IR-signaling is
particularly noteworthy in insulin-responsive tissues such as cardiac myocytes and
vascular smooth muscles that express the AT2. Therefore, understanding what signaling
mechanisms mediate trans-inactivation of IR by the AT2 is of critical importance in
elucidating the pathogenesis of insulin resistance. Elbaz et al., have systematically
demonstrated that the AT2-mediated transinactivation of the IR is not mediated via
orthovanadate-sensitive tyrosine phosphatases. This observation raised the fundamental
question regarding how the AT2 mediates such inhibition of tyrosine phosphorylation of
the IR.
It has been shown previously that the AT2 interacts directly with the ErbB3
receptor of the epidermal growth factor receptor family (EGFR family) in yeast twohybrid system. The interaction between the human ErbB3 receptor and the AT2 receptor
occurred between the cytoplasmic domain (amino acids 671-782) of the human ErbB3
receptor and a truncated AT2 peptide that carried the region spanning amino acids 226363, (spans the third ICL and carboxy terminal domain). Thus, AT2 receptor could also
function via direct interaction with other receptors. Studies using mutated and chimeric
AT2 receptors showed that replacing the third intracellular loop (ICL) of the AT2
receptor with that of the AT1 abolishes the interaction between the ErbB3 and the AT2 in
yeast two-hybrid assay. Thus the interaction between the AT2 receptor and the ErbB3
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receptor seems to require the region spanning the third ICL and carboxy terminus of the
AT2 receptor. Because IR is an RTK, we hypothesized that the AT2 may use a similar
mechanism in inhibiting the tyrosine phosphorylation of IR. Our results suggest that 3rd
ICL and C-terminal cytoplasmic domain of the AT2 are involved in inhibition of tyrosine
phosphorylation of IRȕ subunit. Thus it is possible that the transient expression of the
AT2 results in association of the region spanning 3rd ICL and C-terminal cytoplasmic
domain of the AT2 with cytoplasmic domain of the IR in both ligand-dependent and
ligand-independent manner. Such association could contribute to an alteration in the
conformation of the ATP binding domain or tyrosine kinase domain of the IR (as both
regions were part of the cytoplasmic domain of IR that interacted with the AT2 in Yeasttwo hybrid assay) and prevent normal tyrosine phosphorylation of IR that occurs in
response to insulin.
Our results further indicate that the AT2-IR association is orthovanadateinsensitive. What molecular mechanisms are involved in facilitating the AT2-IR
association is yet to be elucidated. The AT1 receptor is known to internalize in response
to ligand binding and a ȕ-arrestin-mediated mechanism is responsible for AT1
internalization (12). However, it is suggested that the AT2 does not associate with ȕarrestin. Therefore the mechanism by which the AT2 associate with IR and prevents
tyrosine phosphorylation is yet to be unraveled.
However, an intriguing finding from our studies would shed some light regarding
this mechanism. First, we show that while the AT2-IR association is insensitive to both
orthovanadate and pertussis toxin, the AT2-mediated inhibition of phosphorylation of IR
is partially sensitive to PTX. Many AT2-mediated signaling mechanisms are shown to be
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sensitive to PTX. PTX is known to exert its effects via ADP-ribosylating the Gi-alpha
subunit. Therefore, our observation that the AT2-mediated inhibition of phosphorylation
of IR is partially sensitive to PTX implies possible involvement of Gi-protein in this
event.
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CHAPTER III
ANGIOTENSIN II RECEPTORS-INSULIN RECEPTOR COMPLEX
FORMATION IN HYPERTENSIVE RAT HEART
3.1

Introduction

Coexistence of insulin resistance, hypertension and obesity increases the risk of
cardiovascular diseases and predisposes these patients towards metabolic syndrome (1,
2). More than 16 million Americans have diabetes and 65% of deaths in diabetic
conditions occur due to heart attack and stroke. The asymptomatic nature of insulin
resistance contributes to the lack of early diagnosis of this condition. This poor prognosis
combined with a potential risk for cardiovascular diseases make these conditions a
leading medical concern. Several studies have implicated a role for the hormone Ang II
to be involved in the development of hypertension and insulin resistance (3-7). It has
been suggested that a negative cross-talk between the Ang II and insulin signaling system
is the underlying cause for the development of insulin resistance in hypertensive
conditions (3, 7, 8). The renin-angiotensin-aldosterone system possesses various
autocrine and paracrine effects which drive most of the pathophysiological mechanisms
in diabetes-related heart disease (9-11). A synergistic interaction amongst the RAS and
insulin signaling could result in diabetes-related heart disease like diabetic
cardiomyopathy. Diabetes-related heart disease is characterized by a propensity to
develop premature, diffuse atherosclerotic disease, structural and functional abnormalities
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of the microvasculature, autonomic dysfunction and intrinsic myocardial dysfunction.
This is an early metabolic abnormality observed in insulin resistant patients who might
not show significant hyperglycemia and is exacerbated by hypertension and diabetic
nephropathy (10). Many clinical and animal studies have shown that the angiotensin
receptor blockers (ARB) or the angiotensin converting enzyme (ACE) inhibitors can
improve insulin sensitivity considerably in addition to reducing blood pressure (12).
However, a detailed molecular mechanism that leads to an interaction between the two
systems has not been elucidated yet.
Angiotensin II is a multifunctional hormone that regulates cardiac, vascular and
renal actions. Most of the actions of Ang II are mediated via the two main receptors- AT1
and AT2, belonging to the G- protein coupled receptor (GPCR) super family that is
characterized by a seven transmembrane domain topology (13). It is known that the main
functions of Ang II, the cardiovascular responses including vasoconstriction, hypertrophy
and vascular remodeling are brought about by the AT1 receptor. The AT1 receptor is a
359 amino acid protein that mediates its action by coupling to the heterotrimeric Gq and
Gi proteins (14-16). The AT1 receptor is known to couple to the Gi proteins through the
intracellular loops to activate several second messengers. AT1 can activate Gi protein
mediated second messenger pathway via the DRY motif in the 2nd intracellular loop
resulting in the reduction of the intracellular cAMP levels (17-19). The C-terminal
cytoplasmic tail is also involved in Gi protein coupling and activation of phospholipase C
Ȗ (20). Coupling to the Gq protein leads to the activation of phospholipase Cȕ. This in
turn increases diacylglycerol (DAG) and cytosolic Ca2+ and activates protein kinase C
(PKC). The AT1 receptor signaling can also activate tyrosine kinases, both non-receptor
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tyrosine kinase (Jak2, FAK, Pyk) and receptor tyrosine kinase (EGFR and PDGF),
independent of the G proteins. These G protein independent activation of the tyrosine
kinases are mediated through the YIPP motif in the C-terminal domain of the AT1
receptor (21-23). Sadoshima et.al has shown in COS 7 cells that the cytoplasmic region
of the AT1 receptor spanning the amino acids 312 and 337, specifically the
phosphorylation at the tyrosine residue at position 319, is required for the transactivation
of EGFR (24). Activation of these RTKs along with AT1 can regulate downstream
signaling Ras-Raf-MAPK pathway and downstream transcription factors such as Signal
Transducer and Activator of Transcription (STAT) which plays an important role in
cardiac hypertrophy (25). The AT1 receptor is also known to induce changes in
phosphorylation pattern in some of the receptor tyrosine kinases (RTK) like the IR (7,
26). The AT2 receptor is a 363 amino acid protein that shows approximately 30%
primary sequence similarity with the AT1 receptor (27-29). The distributions of these two
receptors are very different; the AT2 receptor is highly expressed in fetal tissue and the
ratio of AT1/AT2 changes significantly after birth. In adult tissues, the AT2 receptor is
expressed in kidney, uterus, heart and adrenal medulla (30, 31). AT2 is known to mediate
its actions by inhibiting the AT1 mediated signaling and hence is thought to be a
cardioprotective molecule (32-34). Experimental evidences suggest a role for the AT2
receptor also in mediating changes in the RTKs via activation of phosphatases or by
association with the receptor (35-41).
Insulin, the major hormonal regulator of glucose transport acts by stimulating
glucose transport and inhibiting gluconeogenesis. The complex signaling pathway that
stimulates glucose transport is mediated through the insulin receptor (IR), a member of
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the Receptor Tyrosine Kinase (RTK) family (42). RTKs are membrane proteins that play
a critical role in mediating various cellular processes like cell growth, differentiation,
metabolism and migration(43). Radiolabelled insulin binding studies were performed for
biochemical characterization of the receptor in the early seventies. These studies in
conjunction with crystallography and mutational studies of the IR subunits in the 1980s
demonstrated the structure-function relationship of IR and specifically receptor tyrosine
kinase domain. The insulin receptor is composed of two Į subunits that are each
connected to a ȕ subunit and to each other by disulfide bonds. The insulin signaling
pathway is initiated when insulin binds to the alpha subunit of the insulin receptor leading
to a conformational change in the extra cellular region of the beta subunit which is
transmitted through the transmembrane region to the kinase domain. IR catalyzes the
phosphorylation of various protein substrates; first being the receptor itself by
transferring a gamma phosphate group from ATP to the tyrosine residues on the
receptor/receptor substrates (44-49). Based on the affinity labelling, epitope mapping and
chimeric constructs, the ligand binding site is placed within the first 500 amino acids of
the alpha subunits. The important functional regions in the ȕ subunit include the ATPbinding domain and the autophosphorylation sites, specifically the tyrosine residues
Y1158, Y1162 and Y1163 in the activation loop (A loop). A series of phosphorylation
events in different regions such as the kinase domain, cytoplasmic carboxyl terminus and
the juxtamembrane domain then lead downstream phosphorylation of the IR substrates
IRS (1-4), phosphoinositol-3-kinase (PI3K), Src homology collagen (Shc), Growth factor
receptor-bound protein (Grb) and Janus kinase (Jak2). These proteins then recruit the
downstream effector molecules that activate different signaling systems (50-52).
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The cell culture and in vivo studies performed to understand the cross-talk
between the Ang II and insulin signaling pathways showed that the AT1 receptor
activates the tyrosine phosphorylation of different substrates of the insulin signaling
pathway via Jak2 (4). This phosphorylation of the IRS 1 and 2 mediated by Ang II is
different from the effect of phosphorylation by insulin and leads to decreased enzymatic
activity of PI3K (53). It has also been shown in studies on rat aorta smooth muscle cells
(RASMC) that Ang II can induce serine phosphorylation of the components in insulin
signaling pathway including the insulin receptor, IRS 1 and PI3K (54). Another study in
human umbilical vein endothelial cells have shown that the serine phosphorylation of the
insulin signaling system is made possible by the activation of C-Jun N- terminal kinase
(JNK) and extracellular signal-regulated kinase(ERK1/2) (55). It is well established that
serine phosphorylation of IRS attenuates the insulin signaling and is a marker for insulin
resistance. In addition to these intracellular events, previous results from our lab suggest
that receptor level cross talk also occurs between IR and Ang II receptors. We observed
that the amount of insulin binding to the insulin receptor is reduced on exposure to Ang
II, and AT1-IRȕ complex was formed in response to Ang II treatment for a period of 2
hours. Since the binding of the hormone to the receptor is the first step in mediating any
signaling events, this AT1 mediated inhibition of insulin binding to the IR could be a
crucial step for the development of insulin resistance in hypertensive conditions. In vivo
studies using genetically modified animals or rats chronically treated with Ang II also
show an interaction between the two signaling systems (8, 56, 57). There is increasing
evidence to suggest that the AT1 and AT2 receptors might have antagonizing actions and
the effect of Ang II is a balance of expression of the two receptors in the target tissue (5885

60). Activation of the AT2 receptor is known to attenuate or inhibit the AT1 receptor
mediated cell growth and promotes differentiation and apoptosis in various cell types (6163). The AT2 receptor is also known to have a negative cross-talk with many receptor
tyrosine kinases (RTK) like FGFR, EGFR and IR. This signaling is brought about by
inhibiting the autophosphorylation of the RTK (37). The AT2 receptor is known to
activate a number of protein phosphatases like SHP1 and these phosphatases play an
important role in the negative cross-talk with the RTKs. The AT2 receptor can inhibit the
ERK signaling cascade activated by the AT1 receptor or receptor tyrosine kinases (36,
37, 64). Our lab has previously reported an interaction between the ATP-binding domain
of ErbB3 receptor, an RTK, and the AT2 receptor in a yeast-two hybrid assay. These
experiments demonstrated that the 3rd intracellular loop and the cytoplasmic tail of the
AT2 receptor were essential for this interaction to occur (40, 41). It has been shown that
the AT2 receptor can inhibit insulin mediated signaling by influencing the
phosphorylation pattern of the tyrosine kinase (35, 64). However, Elbaz et.al has shown
that the AT2R mediated transinactivation of IR is not brought about by orthovandatesensitive tyrosine phosphatases (64). We have shown that transient expression of the
AT2R in Chinese Hamster Ovary cells results in IRȕ-AT2 complex formation and
inhibition of phosphorylation of IRȕ. In this study, the use of several mutants of the AT2
receptor suggested that the 3rd intracellular loop and the C-terminal cytoplasmic domain
of the AT2 receptor were crucial for the receptor level association and subsequent
inhibition of IRȕ autophosphorylation. We have also observed the orthovanadate
insensitive AT2-IR association in human breast cancer cell line MCF7. In addition, the
association between the two receptors was insensitive to Pertussis Toxin while the AT2
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mediated inhibition of the phosphorylation was partially sensitive to PTX. These results
implied that the AT2R could inhibit IR signaling in multifaceted manner.
In heart tissue, the expression of the AT1 and AT2 receptors is species dependent
and the relative proportion is known to play a role in cardiac remodeling and cardiac
hypertrophy (16, 60). AT1 receptor regulates the expression of NO synthase and
stimulation of the AT1 receptor leads to decreased nitric oxide (NO) production in
vascular smooth muscle cells (65). Ang II acting via AT1 receptor can also induce an
increase in oxidized LDL due to an increased generation of the reactive oxygen species
(ROS) and increase in the intracellular calcium levels by activating the production of the
second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG). All of these
events can be related to essential hypertension, atherosclerosis, left ventricular
hypertrophy, cardiac heart failure and restenosis (66-68). Angiotensin II type I receptor
blockers (ARB) are proven to be effective in treating hypertension, restenosis and heart
failure (69, 70). The selective blockade of the AT1 receptor using an AT1 specific
blocker could result in an activation of the AT2 receptor. Activation of the AT2 receptor
is considered to be cardio protective since the AT2 receptor mediated signaling opposed
the AT1 receptor activation. In contrast to the well established role of the AT1 receptor in
the development of hypertension, the role of the AT2 receptor is still controversial (71).
There are contradicting reports on the role of the AT2 receptor in cardiac hypertrophy
(32, 72-74). AT2 mediated signaling can result in vasodilation via the bradykinin/NO
pathway and thus improve cardiovascular physiology (75). AT2 receptor deficient mice
are more prone to heart failure and the chance of survival after myocardial injury is
considerably reduced in these mice suggesting a positive role for the AT2 receptor in
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cardiovascular physiology (76). There are contradicting reports on AT2 mediated
attenuation of cardiac hypertrophy and increase in cardiac hypertrophy (72, 74). There is
a recent report of the AT2 mediated reversal of autophagy in neonatal cardiomyocytes
using adenovirus expressing high ratio of AT2:AT1. However, a long term stimulation
of the AT2 receptor as a result of ARB treatment or pathological conditions is not known
completely.
Role of adipocytokines in modulating insulin resistance, obesity and
cardiovascular diseases has been gaining a lot of research focus (77, 78). Once thought as
potent biological molecules solely derived from adipocytes, it is now known that these
signaling molecules can be produced in other tissues including heart and recent
experimental evidences shows that it could act as cardiovascular markers in addition to
regulating fatty acid and glucose metabolism by acting in an autocrine or paracrine
fashion. Leptin, the satiety hormone is known to exert its effect on glucose uptake and
fatty acid oxidation. Leptin acts by binding to its receptors mainly in the central nervous
system and other tissues such as adipose tissue. Leptin receptor activates the STAT3
pathway and PI3K pathway (79). Leptin and its receptors are present in heart (80) and is
known to have antilipolytic actions and cardioprotective action (81-84). Mice that are
deficient in leptin or have leptin receptor mutations have deposition of lipids in non
adipose tissue leading to cellular dysfunction. Lipid accumulation in heart can be
detrimental leading to heart failure and contractile dysfunction (85). Leptin acting
through multifaceted cell signaling is known to produce cardiac hypertrophy and could
play a role in cardiac remodeling after cardiac injury. The possible signaling mechanisms
of action of leptin includes the activation of Jak/STAT pathway that leads to
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phosphorylation of STAT and translocation into the nucleus, activation of the SHP2Grb2-SOS complex via Jak2 which results in activation of Ras and phosphorylation of
ERK and p38 which translocates into the nucleus to activate GATA4 and finally
activation of the RhoA/Rho kinase pathway that results in a reduction in the C-actin
levels which can induce cardiac hypertrophy through activation of MAPK or the
transcription factor serum response factor (86-88). Adiponectin is a hormone implicated
in improving insulin sensitivity and decrease in adiponectin is a risk for metabolic
syndrome. Increased plasma adiponectin levels are associated with lower risk for
cardiovascular diseases (89-91). A decrease in adiponectin mRNA and protein levels has
been reported in a local cardiac adiponectin system in the heart in conditions of dilated
cardiomyopathy (92). Plasma adiponectin levels are usually decreased in ischemic
conditions, but recent studies suggest that adiponectin is increased in heart failure under
non ischemic conditions and that high levels of adiponectin is a poor prognosis of heart
health. The high adiponectin levels were due to release of the hormone from the heart
into the peripheral circulation in proportion to the left ventricular dysfunction in heart
failure patients (93, 94). Resistin is a hormone that is known to be activated in conditions
of insulin resistance and there are recent reports of elevated levels of resistin in
cardiovascular diseases (95-104). Treatment of adult mouse cardiomyocytes with resistin
results in reduced glucose uptake by these cells (105). Heart relies upon glucose
metabolism for majority of its energy requirements and increased resistin levels could
result in cardiac insulin resistance. An interesting observation was made in neonatal rat
cardiomyocytes which reports an increase in resistin RNA and protein level expression
upon mechanical stretching. PPARȖ is a major regulator of resistin and an upregulation of
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PPARȖ results in reduced resistin expression (106, 107). There are contradicting
evidences for the effect of these molecules in cardiovascular morbidity and further
research is required for the clinical relevance of these hormones in cardiovascular
diseases.
Much remains unclear in the pathogenesis of insulin resistance in hypertensive
patients. A number of genetic factors and acquired factors or environmental factors are
likely to be involved in the pathophysiology of such conditions. These evidences led us to
our question- what happens to the insulin signaling pathway in a hypertensive rat heart in
which both AT1 and AT2 receptors are activated. A mild increase in blood pressure is
sufficient for an increased risk for diastolic dysfunction, myocardial infarction, coronary
artery disease and insulin resistance. Using a genetic model of hypertension such as the
spontaneously hypertensive rat will give an insight into the metabolic changes that are
present in a condition where hypertension and diabetes mellitus are fully developed.
However, using an early hypertensive model will allow us to track the early signaling
steps that are impaired and the transition from normal insulin signaling to a dysfunctional
insulin signaling system. Based on the data from the literature and results from our own
lab regarding the role of Ang II in modulating insulin signaling pathway, we posited that
the Ang II receptors could associate and modulate the IR and its signaling mechanisms
and also affect the expression profile of various other markers such as adipokines in heart
tissue. In this present study, we have examined the changes in the insulin signaling
pathways that result on Ang II administration in healthy rats maintained on a 2% salt diet
with 150ng/kgBW/min Ang II with their respective controls by investigating the
interaction of the two angiotensin II receptors with the insulin receptor in the heart tissue
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of these rats. We, for the first time, report evidence for a complex formation between the
two receptors in heart tissues. This could be a novel mechanism for the development of
insulin resistance in hypertensive conditions.
3.2

Materials and methods

3.2.1 Materials
The reagents for SDS-PAGE and immunoblotting were obtained from Bio-Rad
laboratories (Richmond, CA) or Sigma-Aldrich Corp. (St.Louis, MO). The ECL western
blotting kit was procured from Amersham Biosciences (Piscataway, NJ). All primary,
secondary and agarose conjugates antibodies were purchased from Santa Cruz
biotechnology (Santa Cruz, CA). The iScript One Time SYBR Green RT PCR kit was
obtained from Bio-Rad laboratories (Richmond, CA)
3.2.2

Tissue samples
The heart tissues for this experiment were kindly provided by Dr. Alan Sved,

Department of Neuroscience, University of Pittsburg. Tissues were collected from 10week old SD rats that were placed on 2% NaCl with subcutaneous infusion of 150ng Ang
II/Kg body weight/min for a period of two weeks. The control rats received isotonic
saline solution and were maintained on normal rat chow (0.1% NaCl). The tissues were
flash frozen and stored at -80oC until used.
3.2.3

Tissue preparation for western blotting
The heart tissues were powdered in liquid nitrogen and solubilized in the lysis

buffer [1% Nonidet P-40, 100mM NaCl, 75mM Tris–HCl, pH 7.4 50mM, NaF and 1%
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protease inhibitor cocktail (containing 34.84mg/ml PMSF, 1mg/ml aprotinin and 1mg/ml
pepstatin in 100% ethanol)] as described previously. These lyses conditions solubilised
membrane proteins and the cell debris was removed by centrifuging at 1000g for 5
minutes. Protein concentrations were determined using the Bio-Rad DC assay kit. The
protein concentrations of all lysates were adjusted to the same amount and divided into
two - one half for determining the levels of ȕ actin and other half for
immunoprecipitation. All the graphical representation of the band intensities is calculated
as percentage change with the band intensity in the control tissues taken as 100%.
3.2.4

Immunoprecipitation and SDS-PAGE:
For all co-immunoprecipitation experiments lysates containing 800μg of total

protein was used. For immunoprecipitation, the lysates were pre-cleared by incubation
with 20μL (0.5mL agarose/2mL) of agarose protein G plus for 30 minutes on ice to
reduce non specific immunoglobulin binding. The lysates were centrifuged at 1000g for 5
minutes at 40C. The pre-cleared supernatant was incubated with agarose conjugated
rabbit anti IRȕ antibody (500ȝg/0.25mL of agarose in 1mL) for 4-6 hours on a rocker at
4oC. The pre-cleared lysates incubated with agarose protein G plus for 4-6 hours served
as a negative control. Immunoprecipitated samples were centrifuged at 1000g x 5min and
the pellet was washed with PBS and centrifuged again to remove any unbound agarose
conjugated antibody. The immunoprecipitated proteins were separated on 10% SDS
polyacrylamide gel and subjected to immunoblotting with goat anti-AT1 or anti-AT2
antibody to visualize the bands. To identify the phosphorylation pattern of the IR or IRS
1, the nitrocellulose membrane was immunoblotted with mouse antiphosphotyrosine/phosphoserine antibody. For testing the association of IRS 1 with IR,
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the membrane was blotted with mouse anti IRS 1 antibody. The rainbow marker was also
loaded in one of the lanes of the SDS-PAGE gels used for separation of the proteins to
identify the molecular weights of the bands. ECL Western Blotting Analysis System was
used to visualize the presence of the AT1/AT2 or IR in the immunoblots generated,
according to manufacturer’s instructions (Amersham Biosciences). To determine the
protein concentrations of IR or ȕ-actin, the tissue lysates were separated by SDS-PAGE
and subjected to immunoblotting with anti-IR antibody or anti- ȕ-actin antibody. The
NIH Image Scan (Image J) program was used to quantify the intensity of the bands
present on the autoradiogram. All the Image J results were normalized to beta-actin.
3.2.5

RNA isolation
RNA was isolated from three different tissues from each group using the RNeasy

isolation kit from Qiagen as per the manufacturer’s protocol. RNA was quantified using
the NanoDrop (Thermo Scientific) and the quality was assessed by absorbance ratio
A260:A280.
3.2.6

Real time PCR
Total RNA isolated from heart tissues were used for the qPCR using the BioRad

IScript SYBR Green RT-PCR kit using the Bio-Rad iCycler iQ. The primer sequences
are given in the table 3.1.
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Table 3.1: Sequences of Real Time PCR primers
Gene

Sense primer

Antisense primer

E actin

TGTCACCAACTGGGACGATA

CTGGGTCATCTTTTCACGGT

Adiponectin

AATCCTGCCCAGTCATGAAG

GGTATCCCATTGTGACCAGG

Leptin

GAGACCTCCTCCATCTGCTG

CTCAGCATTCAGGGCTAAGG

Resistin

ACTTCAGCTCCCTACTGCCA

AGCTAGTGACGGTTGTGCCT

3.3

Results

To evaluate the effect of Ang II in the progression from a hypertensive condition
to an insulin resistant model, we analyzed the molecular mechanisms occurring at a
cellular and transcriptional level in heart tissues from hypertensive rats and control rats.
The analyses of the results are given below.
3.3.1

Increased blood pressure in SD rats subjected to 2% NaCl diet and 150ng Ang

II/Kg BW/hr
10-week old SD rats were maintained on a 2% NaCl diet along with 150ng Ang
II/KgBW/min administration. The control rats received 0.1% NaCl and isotonic saline.
Blood pressure was significantly elevated in SD rats receiving subcutaneous infusion of
Ang II in combination with high salt diet as after the first week of treatment compared to
the control rats. The increased level of blood pressure was maintained for the second
week of treatment. The blood pressure measurements were kindly provided by Dr. Alan
Sved and are provided in table 3.2. A plasma glucose analysis did not show any
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significant change in the two groups even though the treated animals had slightly
elevated levels of glucose.
Table 3.2: Treatment given to SD rats and the blood pressure data at the end of
two weeks for SD rats
Treatment

Baseline

Number of

1 week

Number of

2 week

Number of

Avg mean

animals

Avg

animals

Avg mean

animals

pressure

mean

pressure

pressure
Ang II +

101.81

N=8

140.29

N=8

144.5

N=8

93.97

N=5

94.53

N=5

94.6

N=5

2%NaCl
Saline+
.01%NaCl

95

Blood pressure, mmHg

200

Figure 3.1:

AngII +2%NaCl

n=8

Control

n=5

150
100
50
0

0-week

1-week

2-week

Blood pressure measurements.
Treatment (2% NaCl and 150ng/KgBW/min of Ang II) was started
when the rats were 10-weeks old and continued for two weeks. The
statistical significance for changes in blood pressure was
determined using Students T-test. Blood pressure changes for rats
maintained on Ang II and NaCl treatment was p<0.05.

3.3.2

Angiotensin II stimulated increased serine phosphorylation of the IRȕ
Our studies indicated an increased blood pressure in the absence of an increase in

the plasma glucose levels in Ang II treated rats. Since insulin resistance is a condition
where a clinically significant hyperglycemia and hyperinsulinemia may not be evident,
we analyzed the signaling pattern of the IR. Phosphorylation is one of the key events in
insulin mediated signaling. We observed an increased serine phosphorylation of the IRȕ
(Figure 3.2a). It has been previously shown that Ang II increases serine phosphorylation
of the IR and IRS 1 and of the p85 subunit of PI 3-K. Serine phosphorylation of the
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insulin receptor inhibits the further insulin signaling events. Thus our data suggests that
in response to salt diet and Ang II treatment, the insulin signaling in the heart tissue
follows a pattern that could eventually lead to a hyperglycemic condition and play a role
in the development of early insulin resistance.
3.3.3 Effect of Angiotensin II on tyrosine phosphorylation of the IRȕ and IRS 1
Insulin exerts its effects by binding to the receptor tyrosine kinase which leads to
the autophosphorylation of the insulin substrates at residues 1158, 1162 and 1163 and
initiates a cascade of downstream tyrosine phosphorylation events and a major substrate
for the insulin tyrosine kinase is the IRS 1. To determine whether the receptor level
association of the Ang receptor with the IRȕ result in a change in the signaling pattern of
insulin, we measured the phosphorylation pattern of the IRȕ subunit and IRS 1 using anti
phosphotyrosine antibody and specific phosphorylation of the tyrosine residues on the
IRȕ subunit using anti-phospho insulin receptor ȕ tyrosine 1162/1163. Our results
showed an increased tyrosine phosphorylation of the IR (95kDa) and specific tyrosine
residues on the IRȕ subunit. We also noticed an increase in the tyrosine phosphorylation
of the IRS 1 (170kDa) and an increased co-precipitation of the IRS 1 in the samples
treated with Ang II. The protein levels of the insulin receptor were similar in all the
lysates as shown in the figure 3.4.
Several studies on the cross-talk between angiotensin II and insulin signaling
pathways have shown that AT1 receptor can induce increased tyrosine phosphorylation
of the insulin receptor substrates 1 and 2 (IRS 1 and 2). This signaling is mediated via a
G protein independent pathway. AT1 receptor can associate with the Jak2 tyrosine kinase
upon Ang II activation. The phosphorylated IRS 1 binds and activates the
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phosphatidylinositol 3-kinase pathway and this plays a major role in bringing about the
insulin mediated signaling effects. The increased tyrosine phosphorylation of the IRS 1
observed upon Ang II exposure however does not lead to an increased PI3-K activity.
a)

Conditions

Ang II
NaCl
AgaroseIRE

+

+
+
+

+

+
+
+
P

Ser
95kDa

C1 T1 C2 T2

300
Ang II+ 2% NaCl

Control

% increase in pS of IR E

250
200
150
100
50
0
Control 1

Figure 3.2:

Treated 1

Control 2

Treated 2

Changes in phosphorylation pattern of the IRȕ and IRS 1 in rat
heart tissues
a) Autoradiogram showing the levels of serine phosphorylation of
the IR ȕ in heart tissue lysates. In this experiment, the
immunoblots were probed with mouse anti-phosphoserine
antibody. The control heart tissue lysates showed a negligible
amount of serine phosphorylation whereas the treated samples had
much higher levels of serine phosphorylation. All data shown here
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are from two different tissue samples and the graphs are
representative of independent experiments performed at least three
different times. b) Immunoblot representing the IRS 1 tyrosine
phosphorylation in control and treated heart tissues from rats. The
various treatment and immunoprecipitation conditions are given in
the box. c) An example of the autoradiogram showing the
increased tyrosine phosphorylation of the IRȕ in hypertensive heart
tissues. Initial protein concentrations used for all
immunoprecipitations was the same (800ȝg). d) Autoradiogram
showing the changes in the specific tyrosine residues 1162 and
1163 of the IRȕ. A graphical representation of the levels of serine
phosphorylation of the IRȕ, tyrosine phosphorylation of the IRS 1
and IRȕ and phosphorylation of tyrosine 1162/1163 of IRȕ in
control and treated groups from three separate experiments are also
given along with each of the autoradiograms The percentage
increase in treated groups was approximately 2- 4 fold more than
the control rats. Percentages were calculated with the controls
taken as 100%. All the quantification was performed using the
NIH image J scan analysis. Statistical significance was calculated
using Students T-test, p <0.05
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b)
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Figure 3.2 (continued)
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Figure 3.2 (continued)
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Control 2
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d)
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+
+
+
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+
+
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+
+
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Control 1 Treated 1 Control 2 Treated 2
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300
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100
50
0

Control 1

Treated 1

Control 2

Treated 2

Figure 3.2 (continued)

3.3.4

Ang II stimulates complex formation of AT1 receptor with IR in early hypertensive

heart
AT1 receptor mediated transactivation of RTKs like EGFR results in coimmunoprecipitation of the two receptors. Since IR is an RTK like EGFR, we performed
the co-immunoprecipitation studies using heart tissue lysates from SD rats that were
exposed to Ang II in combination with high salt diet and control rats that received saline
and normal chow to test whether the Ang II receptors associate with the IR. There was
enhanced AT1 receptor co-precipitation with the IRȕ in heart tissues that were obtained
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from rats exposed to Ang II and high salt diet as was visualized by a strong band
corresponding to the molecular weight 45kDa (Figure 3.3). An enhanced association of
IRS1 was also observed when the tissue lysates were immunoprecipitated with IRȕ
antibody.
NIH Image J analysis was performed to determine the intensity of the bands. A
graph representing the differences in the intensities of the bands at 45kDa is shown in
figure 3.3. There was at least 2-3 fold increase in the band intensity for the
immunoprecipitated samples from the Ang II treated rat heart tissues. There was no
significant difference in the AT1 receptor or IR expression levels as was seen from the
western blot analysis of the tissue lysates.
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Figure 3.3:

Treated 1

Control 2

Treated 2

Complex formation of the AT1R-IR and IRS 1-IR
An example of the autoradiograms showing enhanced AT1 and
IRS 1 co-precipitation with the IRȕ subunit in heart tissues from
rats treated with 150ng/KgBW/min Ang II and 2% NaCl for two
weeks. The various treatments are given in the box above the
autoradiogram. The results shown are with two different tissues
from the control and treated group respectively. Initial protein
concentrations used for all immunoprecipitations was the same in
all lysates (800ȝg). A strong band corresponding to 45kDa was
visible in the treated samples after probing the nitrocellulose
membrane with goat anti AT1 antibody. A graphical representation
of the levels of AT1 and IRS 1 co-precipitated with the IRȕ in
control and treated groups from three separate experiments. A very
low level of AT1 association was seen in the control group which
was taken as 100%. The percentage increase was calculated for
AT1 immunoprecipitated with IR in treated groups which was
approximately 3 fold more than the control rats. Similar calculation
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was done for IRS 1 immunoprecipitation. All the quantifications
were performed using the NIH image J scan analysis. Statistical
significance was calculated using Students T-test, p <0.05
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Figure 3.3 (continued)

3.3.5

Ang II stimulates AT2- IR sequestration
Expression of the AT2 receptor is increased in cardiovascular injury, myocardial

infarction and hypertension. An intriguing question that arises is the role of the AT2
receptor in cardiovascular diseases and insulin resistance. Elbaz et.al has shown that the
AT2 receptor inhibits the insulin mediated tyrosine phosphorylation of the IR. We have
also seen that the AT2 receptor co-immunoprecipitates with the IRȕ in Chinese Hamster
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Ovary cells. To verify the data that was observed in cell culture conditions in an ex vivo
system, we performed immunoprecipitation of the IRȕ in the heart tissue lysates from
hypertensive and control rat hearts. We observed that the AT2 receptor co-precipitated
with the IRȕ as was evidenced by the intense broad band corresponding to the molecular
weight of ~ 45kDa. The level of the AT2 receptor that co-precipitated with the IRȕ in
control tissue lysates was very low. An autoradiogram showing the difference in the coimmunoprecipitation between the treated and control rat heart tissue lysates is shown in
the figure 3.4. NIH Image J analysis was performed on these autoradiograms to quantify
the differences between the levels of the AT2 that co-precipitated with the IRȕ.
Approximately 3-fold increase was observed in the level of the AT2 in treated heart as
compared to the control. A graph representing the percent change in the amount of AT2
is given in figure 3.4.
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Figure 3.4:

Treated 2

95kDa

IB: IRE

AT2-IR complex formation in hypertensive heart tissue
Autoradiogram showing the levels of AT2 that co-precipitates with
the IRȕ. The experiment was similar to that of AT1
immunoprecipitation except that the nitrocellulose membrane was
probed with goat anti AT2 antibody. Western blots showing the
protein levels of ȕ actin and IR in the tissue lysates. A graphical
representation of the AT2R co-precipitation with the IRȕ is shown.
Calculations were done in a similar manner to that of AT1
measurements taking the control as 100% association. The bars
here represent the amount of AT2 that was immunoprecipitated
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with the IR in control and treated groups from three separate
experiments.

3.3.6

AT1/AT2-IR complex formation in genetically predisposed model of hypertension-

SHR:
The receptor level association observed in our early hypertension model was
confirmed using a rodent model which is genetically predisposed to hypertension.
Spontaneously hypertensive rats (SHR) are characterized by high blood pressure and
insulin resistance. Heart tissues from these rats and their corresponding controls, WKY
rats, were used to analyze the complex formation between Ang II receptors and IR. We
observed that both the receptors co-immunoprecipitate with the IR in heart tissue lysates
from SHR. The results are given in figure 3.5.
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Ang II receptors-IR association in SHR heart.
The figure shows autoradiograms showing the strong band
corresponding to AT1 and AT2 in heart tissue from SHR rats and
the quantification using Image J. The percentage change was
calculated taking the controls as 100%

3.3.7

Effect of Ang II treatment with 2% NaCl diet on expression of adipocytokines
To elucidate the role of Ang II infusion along with the salt diet on the gene

expression pattern in heart tissues, we performed an exon array analysis. An interesting
outcome of the data analysis was the down regulation of the adipocytokines leptin,
resistin and adiponectin and the nuclear transcription factor PPARȖ by 5-40 fold in heart
tissues. To confirm the observations from the array analysis a quantitative PCR was
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performed to measure the RNA levels of the adipokines in hypertensive heart tissue. As
is given in the graph, we see a decreased expression of adipocyte-related genes with Ang

Fold difference in comparison to the controls

Figure 3.6:
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the relative fold difference to the untreated samples after
normalization to the house keeping gene ȕ actin

3.4

Discussion

Approximately 47 million US residents suffer from metabolic syndrome
according to The Third National Health and Examination Survey (108). Insulin resistance
seems to be an important feature in the pathophysiology of metabolic syndrome, also
known as insulin resistance syndrome, which increases the risk for other diseases such as
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obesity, hypertension, hyperlipidemia, inflammation, atherosclerosis and cardiovascular
disease. Resistance to insulin action results in reduced glucose uptake which results in a
cluster of abnormalities such as impaired glucose tolerance, hyperinsulinemia,
dyslipidemia, endothelial dysfunction, and increased blood pressure (109). Among the
various disorders that characterize the metabolic syndrome, the crosstalk between insulin
signaling and Ang II signaling has been a research focus due to the overlapping nature of
insulin resistance and hypertension which shares a complex signaling mechanism that lay
the foundation for both conditions. In most of the cases of reduced insulin sensitivity, the
pancreas start synthesizing more insulin to compensate for the reduced glucose disposal
and this hyperinsulinemia is known to induce local RAS (110, 111). Most of the diabetic
complications can be attributed to cardiovascular diseases and the prevalence of
hypertension in diabetics is much higher than in non diabetics. The renin angiotensin
system is also known to negatively affect insulin signaling thereby resulting in insulin
resistance. The RAS can affect the insulin signaling at multiple levels which include an
early interference by regulating the bradykinin accumulation, at an intracellular level
acting via kinases that induce serine phosphorylation of the IR or at a later stage acting
via SOCS3 It is also evident through many clinical studies that both antidiabetic
treatment and antihypertensive drugs can not only improve diabetes and hypertension, but
can act to improve hypertension and insulin resistance respectively. Even though there
has been tremendous progress in the research and treatment of these disorders, these
remain a major contributor to mortality and morbidity throughout the world. In light of
this, it is clear that a multidisciplinary approach is required to understand the global risk
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that these disorders pose with focus on new markers in combination with traditional
markers and lifestyle changes.
A number of studies have shown that the development of insulin resistance in
conditions where RAS is activated occurs by influencing the downstream signaling of the
IR by changes in the phosphorylation pattern of IR, IRS and PI3K which would result in
loss of enzymatic activity of PI3K. This phenomenon is considered to involve Jak2 which
associates with the AT1 receptor and IRS 1 (26, 53). However, Ang II administration is
also known to phosphorylate the serine residues on the IRȕ subunit and IRS 1 by acting
via ERK and JNK (4, 7, 8). The altered tyrosine phosphorylation in combination with the
increased serine phosphorylation could be the possible mechanism of inhibition of insulin
signaling pathway (54, 112-114). Previous studies from our lab using human breast
cancer cells MCF7 has shown that exposure to 100nM Ang II results in AT1-IR
association and that this happened parallel to a reduction in the amount of insulin binding
to the insulin receptor. An important aspect of this study was that a 2h time period was
required for these events to occur in these conditions. Many studies performed earlier
with shorter duration of Ang II exposure did not show a reduction in the insulin binding
to the receptor. In hypertension, the patients are constantly exposed to high levels of Ang
II and this could eventually lead to an insulin resistant condition in hypertensive patients.
In insulin sensitive tissues such as heart which is also a main target of the RAS, disorders
of insulin action can be detrimental which could result in increased lipotoxicity of the
heart and plaques. So in this study we provide an additional mechanism to understand the
crosstalk between the RAS and insulin signaling systems in heart tissues from
hypertensive rats.
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A decline in the body’s responsiveness to insulin might result from a reduced
ability of the skeletal muscle (responsible for majority of insulin stimulated glucose
disposal) to mediate insulin stimulated glucose disposal. However, the whole body
insulin resistance may involve other tissues such as liver, adipose tissue and heart. Heart
is a target tissue for the action of both Ang II and insulin. Myocardial insulin resistance
and metabolic alterations are characteristic features of insulin resistance that increase the
risk for cardiovascular diseases. Diabetic heart is characterized by reduced glucose
uptake and oxidation.
Heart is an energy consuming organ that requires a constant supply of ATP to
maintain its myocardial contraction/relaxation cycle. The major source of ATP
production in the heart is long chain fatty acid (LCFA) molecules and glucose with
preference given to the LCFAs. In an insulin resistant condition, even though the glucose
uptake is reduced in the heart, the LCFA uptake is enhanced. However, this LCFA uptake
and oxidation is not sufficient to prevent the lipid accumulation in the heart.
In heart, both Ang II receptors are known to be present. During myocardial
infarction or heart failure, the receptors are known to upregulated. To understand the role
of these two receptors in influencing the insulin signaling in our early hypertensive rat
heart model, we subjected healthy SD rats to Ang II infusion and 2% NaCl diet. Our
results suggest that the AT1-IR and AT2-IR complex formation is a phenomenon that
occurs in the heart tissue. The small amount of association in non-hypertensive rat heart
tissue could be because of the normal physiological levels of circulating insulin and Ang
II. However, we see a significantly enhanced association of the receptors in hypertensive
tissue in which the RAS is activated. Since both the receptors are sequestering the IRҏȕ
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subunit and we observe an enhanced serine phosphorylation of the IR and IRS 1which is
mediated by the AT1 receptor, we assume that the AT1 mediated actions are playing a
major role in affecting the insulin signaling in this situation. We did not see a change in
the expression levels of IR, AT1 or AT2 in these tissues. It is known that the AT1 and
AT2 receptors can associate with each other. So it could be argued that the AT2
sequestration that is seen in these experiments could be because of the heterodimerization
of the AT1 and the AT2 receptors and not due to direct association of the AT2 with the
IR. However, we have shown in cell systems that the AT2 receptor can interact with the
IR in the absence of the AT1 receptor. The role of AT2 in mediating insulin signaling
events needs more evaluation. This study presents an additional and a novel mechanism
for Ang II mediated modulation of insulin signaling in rat heart.
A global gene expression profiling analysis performed on these heart tissues
identified a number of genes that were up regulated or down regulated in response to Ang
II administration. Among the components of RAS, we saw a downregulation of
angiotensinogen, ACE and Angiotensin type Ia receptor expression. This downregulation
could be the result of exogenous Ang II administration which reduces the synthesis of the
endogenous Ang II. Of interest among the altered gene profiles were the adipocytokines
such as adiponectin, leptin and resistin; all of which were down regulated in treated heart
tissues. Adipocyte derived adiponectin and leptin are molecules that mediate insulin
sensitivity and resistin is implicated in insulin resistance. It is not known whether the
AngII receptors can mediate the regulation of expression levels of these adipocytokines
in heart. Recently Matsushita et al has shown that a local RAS is involved in
adipogenesis and differentiation of the mesenchymal stem cells into adipocytes. But this
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event was inhibited by exogenous Ang II and/or valsartan. A combination of Ang II and
AT2 receptor blocker however restored the adipogenesis in these cells. In these studies,
the Ang II treatment (18 days) with valsartan reduced the expression of the adipocyte
derived cytokines such as adiponectin and leptin, but the treatment of these cells with the
AT2 receptor blocker reversed the inhibition of expression of these cytokines. This study
suggests an important role of the AT2 receptor and RAS in the adipogenesis and
regulation of the adipocytokines in the mesenchymal stem cells. Another study result in
7-week old SD rats infused with Ang II suggests that Ang II can decrease plasma
adiponectin levels due to oxidative stress that is induced by Ang II administration. (115).
We also investigated the effect of Ang II (6 hours) and 2% NaCl on HL-1
cardiomyocytes, but we did not get the reduction in expression of adipokines in these
cells. This could be due to the short duration of the treatment compared to the two-week
treatment in rats. But in a condition where hypertension and insulin resistance co exists,
the AT1 and AT2 mediated events could play a major role in changing the metabolic
profile and could provide insight into the pathophysiology of insulin resistance,
hypertension and obesity. The exact role and mechanism of action of these cytokines in
heart tissue is yet to be completely understood. The relevance of this study is that in
conditions of heart disease, both the Ang II receptors are activated and it is important to
understand the crosstalk between these two receptors and other molecular mechanisms.
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CHAPTER IV
CHANGES IN HEART TRANSCRIPTOME IN EARLY HYPERTENSION MODEL

4.1

Introduction

The signaling mechanisms that lead to the development of cardiovascular diseases
in hypertension are yet to be worked out. Insulin resistance or diabetes mellitus is closely
aligned with coronary heart diseases. Such close association between hypertension and
related metabolic changes (insulin resistance, dyslipidemia, fat accumulation) further
strengthen the need for a systematic analysis to determine how normal or hypertensive
cardiac tissue and vasculature undergoes the transition to pre-diabetic status.
As discussed in the earlier chapter, our results indicate that in addition to the
intracellular events, the cross talk between insulin and Ang II occurs at the receptor level
and that involves association of both Ang II receptors with the IR. In conditions like
hypertrophy or ischemia that activates RAS in the heart, these events can lead to reduced
insulin signaling due to such negative cross talk between the two signaling systems. In
our studies using an early hypertensive rodent model, we observed an increased
association of the Ang II receptors with the IRȕ subunit. Analysis of the downstream
signaling events of the insulin receptor, the phosphorylation pattern of the IRȕ subunit
and IRS1, in these hypertensive rat hearts provides strong incidence towards
dysfunctional insulin receptor even in the absence of hyperglycemia.
124

A multitude of metabolic changes occur in disease conditions that could be due to
a functional alteration of a network of hormones, growth factors, and cytokines or by
changes at the transcriptional level. The changes at the transcriptional level could be due
to induction of certain transcription factors that can act as suppressors or enhancers of
gene transcription or due to the regulation of the different factors that affect the
architecture of mRNA at an alternative splicing level. The human genome sequencing has
unraveled the organization of genes and the arrangement of the genes into exons and
introns, which allow us to explore how the transcriptome is regulated. This combined
with the remarkable advancement in the field of microarray technology has made it
possible to evaluate how the gene expression profile alters during transition of the tissues
from normal physiological status to pathophysiology.
Recent research indicates that 70% or more of the best characterized genes in the
human genome comprise multiple exons and that alternative splicing is prevalent in these
multi exon genes. Alternative splicing is very important in many pathways and processes;
each of these alternatively spliced transcript could be translated into a different protein
with a different function that greatly increases the diversity of the proteins encoded by the
genome (1, 2). Disruptions to the alternative splicing machinery have been implicated in
Alzheimer’s disease, many types of cancers, myotonic dystrophy and cystic fibrosis (2, 3)
Understanding the role of alternative splicing in regulation of gene expression will aid in
identifying pathways that are disrupted in disease and novel potential targets for therapy.
Ang II is a vascoactive peptide that regulates cardiovascular physiology and
vascular pathobiology. The effect of Ang II on various tissues could be a direct effect of
Ang II-induced post-transcriptional and translational events or an indirect effect mediated
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via the activation of certain transcription factors that modulate gene expression pattern.
For example, activation of local RAS in tissues could increase cardiac hypertrophy and
fibrosis without significant changes in blood pressure. A number of lines of evidence
show that Ang II mediates its effects in various cell types by activation of several
transcription factors. Exposure to Ang II in vascular smooth muscle cells or endothelial
cells result in activation of the transcription factors c-fos, c-jun and early growth
response-1. Ang II is also known to activate the signal transducers and activators or
transcription (STAT) and nuclear factor țB. Recent evidence suggests that targeted
disruption of kruppel like zinc finger transcription factor partially inhibits the Ang II
mediated hypertrophy and vascular remodeling. Ets-1, a transcription factor with various
biological roles, is critical for Ang II mediated inflammation and vascular remodeling.
Inflammation is also a major player in the pathogenesis of insulin resistance syndrome
(4). Analysis of the changes in the transcriptome in response to various metabolic
changes will help in a detailed understanding of the disease and disease progression.

4.2

GeneChip Exon Array

Microarray analysis is a very powerful tool for high-throughput gene expression
profiling. The technique reveals the genetic and molecular basis of various complex
diseases and provides a single platform for the analysis of a number of genes
simultaneously. Most microarrays are directed to analyzing changes in transcription at the
gene level and these arrays are not effective tools in determining the distinction between
the different isoforms. Due to the location of the probes, it is also easy to miss certain
transcripts entirely in such systems. GeneChip Exon Array from Affymetrix is a platform
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to interrogate overall gene expression profile and a detailed exon-level expression. In a
conventional 3’ array, the probeset consists of 11–20 probes selected from the 3ƍ end of
the mRNA sequence and employs an oligo dT primed DNA polymerase to generate the
target. This method requires an intact polyA tail in the initial transcript. Transcripts
lacking a 3’ exon because of alternative splicing, non polyadenylation, or other events
that result in a deletion of the 3’ end will not be detected using the 3’ array. However, the
new exon array has 4 probes per putative exon and T7 linked random hexamers are used
for target generation. With almost 6 million features or spots on each array, exon array
will help in further deepening our understanding of the molecular mechanisms behind
complex diseases. The exon array design differs from the 3’ expression array in the
number and placement of oligonucleotide probes and the background correction probe
design. Up to 4 perfect match probes are present for each probe set region In order to
overcome the “probe effect” which arises due to the differences in the probe
hybridization signal, Affymetrix utilizes the probe set design which incorporates a probe
pair that consists of a perfect match (PM) and a corresponding mismatch (MM) probe.
Each of the MM probe is a 25-mer nucleotide which differs from the PM probe in one
nucleotide in the center. The PM probe exactly matches the target and gives signals
produces by both the specific and non-specific binding. The MM probe with the
mismatch at the central nucleotide will give only the non-specific binding. Therefore,
subtracting MM signal from PM signal will give an accurate estimation of the
hybridization signal. In contrast to the 3' approach of using MM probes to measure nonspecific hybridization. exon arrays have no MM probes and instead include a set of
probes designed to detect hybridization due to pure background. Two collections of
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background probes are used in this design-antigenomic background probes and genomic
background probes. Antigenomic background probes are a collection of probes that are
not present in the human genome and hence will not hybridize whereas the genomic
background probes are mismatch probes of the perfect match probes that are present in
regions less likely to be expressed. A schematic of the probe design is given in figure 4.1
that compares the exon array and conventional array.

Figure 4.1:

Probe design of Exon arrays and comparison with 3’ array

In a pathophysiological condition where hypertension and insulin resistance
coexists, the metabolic changes that occur could be reflected at a transcriptional level in
the heart. Even though there are a number of initial studies using microarray to identify
transcriptional changes associated with cardiac hypertrophy, myocardial infarction, heart
failure and primary pulmonary hypertension, there is not sufficient evidence to predict
the changes in the pattern of the transcriptome as a tool to understand the complexity of
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multiple diseases that often co-exist (5-7). In this study, we have used heart tissues from
an early hypertensive rodent model to study the changes in the gene expression profile
and to identify the regulators of these early transcription changes. Since both AT1R and
AT2R are activated in the heart, we raised the following question- how do these opposing
signaling mechanism influence progression towards insulin resistance and metabolic
syndrome? To understand and evaluate the changes in gene expression profile we used
the Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay. This assay and
associated reagents are designed to generate amplified and biotinylated sense-strand
DNA targets from the entire expressed genome.
Knowing what genes are differentially regulated would give clues to the
molecular mechanism that connect insulin resistance and hypertension and the
differences in the transcription profiles could provide markers for the onset on insulin
resistance in a hypertensive condition.

4.3

4.3.1

Materials and methods

Materials
The reagents and kits required for performing the exon array was obtained from

Affymetrix (Santa Clara, CA). RNA isolation was isolated using kit obtained from
Qiagen (Valencia, CA).
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4.3.2 Tissue samples
All the tissues were provided by Dr. Alan Sved, Department of Neuroscience,
University of Pittsburg. Tissues were collected from 10-week old SD rats that were
placed on 2% NaCl with subcutaneous infusion of 150ng Ang II/Kg body weight/min for
a period of two weeks. The control rats received isotonic saline solution and were
maintained on normal rat chow (0.1% NaCl). The tissues were flash frozen and stored at 80oC until used.

4.3.3

RNA isolation
RNA was isolated from three different tissues from each group using the RNeasy

isolation kit from Qiagen as per the manufacturer’s protocol. Briefly, the heart tissues
were powdered in liquid nitrogen and lysed using guandinium isothiocyanate and
homogenized and loaded onto RNeasy silica membrane. This results in binding of all
RNA to the membrane and removal of all contaminants via subsequent washing with
appropriate buffers. RNA was eluted in 15 microliter of water. RNA was quantified using
the NanoDrop (Thermo Scientific) and the quality was assessed by absorbance ratio
A260:A280 to check for contaminating proteins.

4.3.4 Exon arrays
The protocol is optimized for an initial total RNA concentration of 1ȝg which is
subjected to a ribosomal RNA (18S and 28S rRNA) reduction procedure to minimize the
background and increase the sensitivity and specificity. Following the rRNA reduction,
the double stranded cDNA was synthesized using random hexamers tagged with a T7
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promoter sequence. The dscDNA was used as a template to synthesize copies of antisense
cRNA. In the second cycle of cDNA synthesis, random hexamers were used to reverse
transcribe the cRNA to produce single stranded DNA in the sense orientation. DNA
fragmentation was achieved by utilizing an approach that incorporated dUTP in the
second cycle first strand cDNA synthesis which was then treated with uracil DNA
glycosylase and apurinic/apyrimidinic endonuclease 1 that specifically recognizes the
dUTP residues and breaks the DNA strand. Terminal deoxynucloetidyl transferase
covalently linked to biotin was used to label the fragmented DNA.
A schematic of the protocol used for exon array analysis is given in the figure 4.2
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Figure 4.2:

Genechip Whole Transcript sense target labeling assay
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4.3.5

Array analysis
GeneChip Operating Software version 1.4 was used to produce CEL intensity

files. The Affymetrix Expression Console Software was used to normalize the cel files
using the quantile normalization and then data were summarized into Robust Multichip
Analysis Algorithm (RMA). The RMA algorithm fits a robust linear model at the probe
level to minimize the effect of probe specific affinity differences. This approach
increased the sensitivity to small changes between experiment and control samples. The
box plot display was used to normalize the highly skewed array distribution of intensities
using the log2 transformation. The significance of the changes in the gene expression
profile was estimated using Significance Analysis of Microarrays (8) or Cyber-T (9-11).
The criteria for significant changes in gene expression were a > 5 fold change with a q
value =/<2.
4.3.6

Ingenuity Pathways Analysis
Altered genes were analyzed using Ingenuity Pathways Analysis (version 7.5,

CA, USA www.ingenuity.com) by searching for connection of genes, looking for
common regulators and finding the shortest connection between two nodes.
4.3.7

Real Time PCR
Total RNA isolated from heart tissues were used for the qPCR using the BioRad

IScript SYBR Green RT-PCR kit using the Bio-Rad iCycler iQ. The primer sequences
are given in the table 4.1.
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Table 4.1: List of primer sequences for Real Time PCR

Gene

Sense primer

Antisense primer

Renin

GCTTTGGACGAATCTTGCTC

TGAACCCGTGTCAAAGATGA

Angiotensinogen

ATCCACCCCTTTCATCTCCT

CTGGCTACACCTCTTGCCTC

ACE

AGGTGGTGATGTTCCAGAGC

TCATACAGCTCCTTGGCCTT

AT1a

GGAAACAGCTTGGTGGTGAT

ACATAGGTGATTGCCGAAGG

AT1b

ATGACCCTTAACTCCTCTACT

CGTAGAAAAAAACTTCACCCT

AT2

ACACAAACCGGCAGATAAGC

TGCTGGACACCTTTTTAGGG

4.4

4.4.1

Results

Quality control
Box plot- Relative Signal: The relative signal box plot summarizes the

distribution of the ratio of signal for each probe set to the median probe set signal across
all the six arrays (3 control and 3 treated arrays). The box plot analysis confirmed that the
arrays were of good quality as shown in the figure 4.3. The majority of the genes are
centered at the no change mark. Most genes in a microarray study should not change.
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Figure 4.3:

Boxplot of all arrays.
The central boxes represent the inter quartile range. Extreme
values are plotted individually as seen by the dots above and below
the central box

Correlations- Pearson’s and Spearman: The relationship between two variables
was estimated using the standard statistical measures of linear correlation using the
Expression console software. The correlation values are given as a heat map in the figure
4. 4.
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Figure 4.4:

Correlation heat map of the six arrays

Spike controls, labeling controls and internal control genes (house keeping genes)
were monitored to assay data quality and were found to be within the array performance
metrics.
4.4.2

Array analysis
The criteria to select the differentially regulated genes were set according to fold

change (>2) and significance as estimated using SAM (q<2) or Cyber-T (p<0.05). The
number of genes that were downregulated with these criteria was approximately 360 and
the number of upregulated genes was approximately 210. The maximum number of genes
that were altered was found to have a 2-fold difference from the control rats (224 out of
360 among the downregulated genes and 129 out of 210 in the upregulated genes). Below
is a list of genes that were downregulated or upregulated given in terms of fold change
and significance.
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Figure 4.5:

A gene tree depicting the genes downregulated in hypertensive
hearts compared to the control rat heart tissue.
Data here represents altered genes with 5-fold difference and q<2
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Figure 4.5 (continued)

138

Figure 4.6:

Gene tree depicting the upregulated genes in hypertensive rat
hearts based on the criteria of fold change > 2 and q<2
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Figure 4.6 (continued)

Analysis of the transcription profile of hypertensive tissues showed two distinct
trends, on one hand a significant reduction in the expression levels of genes that augment
hypertension and insulin resistance was observed. However, in contrast we also saw
changes in the expression profiles of genes that would reduce the negative effects of
hypertension and insulin resistance implying that two opposing signaling mechanisms are
simultaneously activated in these early hypertensive tissues. The role of these opposing
signaling mechanisms in this early hypertension model is unclear, but it clearly suggests
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an initial attempt to overcome the external factors that are playing a role to change the
metabolic profile of the heart tissue towards a disease condition. A list of genes that
showed varying roles in the pathogenesis of insulin resistance or hypertension is given
below in the tables.

Table 4.2: Downregulated genes that can reduce negative effects of hypertension

ABCD2: Higher ABCD2 score predicts patients most likely to have
true transient ischemic attack
PDE3b: PDE3 inhibitors milrinone is still used in the acute treatment
of heart failure, and cilostazol is used in the treatment of
intermittent claudication
MST 1: Inhibition of MST1 prevents apoptosis and cardiac
dysfunction without affecting cardiac hypertrophy after myocardial
infarction
Tnfrsf11b or Osteoprotegerin: A marker for increased calcification
of myocytes
LOX: Participates in the remodeling of the heart leading to cardiac
dysfunction
Agt (Angiotensinogen): Precursor for Ang II
S100 b: A cardiac injury marker

Table 4.3: Downregulated genes that can reduce negative effects of insulin
resistance
Lipe: Hormone sensitive lipase usually increased in diabetes and hypertrophy
Pck1: Phosphoenolpyruvate Carboxykinase inhibits insulin signaling
Pyg1: Liver glycogen phosphorylase usually increased in diabetes and inhibits
insulin signaling in response to high glucose levels
PLIN: Perilipin; regulator of satiety and marker for obesity
S1c36a2: Solute carrier family 36 (proton/amino acid symporter), member 2
usually increased in diabetes and hypertrophy
Acaca: Acetyl-coenzyme A carboxylase alpha; specific inhibitors used for treating
Metabolic syndrome
Retn: Resist insulin (Resistin); marker for insulin resistance
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Table 4.4: Downregulated genes that can augment negative effects of insulin
resistance and hypertension
Cdo: cysteine dioxygenase required for Taurine biosynthesis
Csad: cysteinesulfinic acid decarboxylase; required for Taurine biosynthesis
Tkt: Transketolase; essential for NADPH biosynthesis.
Cnn: Calponin; maintains Mean Arterial Pressure
C-met:HGFR; Mediates antiatrophic/degenerative and antifibrotic effects on myocardium nonischemic
cardiomyopathy
Scgb1a1: Secretoglobin; Protective role in nephropathy
Ucp1: Mitochondrial uncoupling protein; mitigates reperfusion-induced damage
Nov: Novdel3; Low in abnormal skeletal and cardiac development, cardiomyopathy, muscle atrophy
Alb: Albumin; Poor prognosis marker for heart disease.
PPARg: Master regulator of adipokines; reduced in insulin resistance
Adipoq: Adiponectin; a marker for obesity and cardiac health
Lep: Leptin; regulator of satiety and marker for obesity
Pfkbp1: 6-phosphofructo-2-kinase low: reduced in insulin sensitivity,
dilated cardiac myopathy
Plin1: Reduction cause obesity, resistance to weight loss
Gys2: Glycogen synthase

Table 4.5: Upregulated genes that can reduce negative effects of hypertension
Cryl1: Salt tolerance and tumor suppressor c
Gpsm1: Regulates arterial mean pressure in response to fluctuations
Got1: Glutamate scavenger

These results suggest opposing mechanisms that regulate transcriptional changes
in heart tissues treated with Ang II and NaCl for a period of two weeks.
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To understand the biological themes among the differentially expressed genes, we
used the gene ontology analysis EASE software (12). The analysis identified genes
involved in various molecular and biological themes of which lipid and carbohydrate
metabolism was the most significant. A list of altered genes is given in tables 4.6 and 4.7.
Table 4.6: List of genes involved in carbohydrate metabolism that are changed in
the heart tissues from rats that received Ang II treatment
Carbohydrate metabolism
Gene description
Down regulated genes
Pepck1
Phosphorylase, glycogen
Glycogen synthase 2
ATP citrate lyase
Glucose 6 phosphatase X linked
Glycerol 3 phosphate dehydrogenase 1
6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 1
Protein phosphatase 1 subunit 3B
6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 1
Pyruvate dehydrogenase kinase 4
Aconitase 1
Glucuronidase beta
Up regulated genes
Synaptojanin
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Fold change
85
16
15
9
7
6
3
3
2
2
2
2
2

Table 4.7: List of genes involved in lipid metabolism that are changed in the heart
tissues from rats that received Ang II treatment
Lipid Metabolism
Gene Description
Down regulated genes
PEPCK
Perilipin
Leptin
PPARg
Acetyl coenzyme carboxylase a
ATP citrate lyase
Microsomal GST
Lipase
Glycerol 3 phosphate deyhdrogenase
Uncoupling protein 3
7 dehydrocholesterol reductase
Acetoacetyl CoA synthetase
Acyl CoA synthetase
HMGCS1
Sphingomyelin phosphodiesterase 3
Glycerol 3 phosphate dehydrogenase 2
Lsr
Sphingosine 1 phospholyase 1
PGendoperoxidase synthase 2
Phospholipase D1
Natriuretic peptide Receptor 3
Up regulated genes
Acyl CoA synthetase 6
Crystallin
Phytanoyl CoA hydroxylase

Fold change
85
28
17
10
10
9
8
7
6
6
5
5
5
4
4
4
3
2
2
2
2
1
5
1

Pathway assist analysis was used to represent the networks affected in the
hypertensive heart tissue. Administration of Ang II to rats is known to alter the
expression of genes involved in metabolic pathways involved in various disorders of the
metabolic syndrome. Genes involved in metabolic disorders that were found to be altered
was chosen and the two top networks were taken from the data. The transcription factor
PPARȖ and CEBPĮ seem to play an important role as these were highly connected nodes
in the pathway. Canonical pathways analysis identified the pathways from the Ingenuity
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Pathways Analysis library of canonical pathways that were most significant to the data
set. The analysis and clustering are given in figures. A system of cluster analysis for the
genes described in the networks was created using TIGR multi experimental viewer (13).
This clustering data groups together genes of similar function and gives a better
understanding of how the genes involved in lipid and carbohydrate metabolism are
grouped together.

Figure 4.7:

Pathway analysis network involving differentially expressed genes
from carbohydrate and lipid metabolism groups in metabolic
disorders-network 1
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Figure 4.8:

Hierarchical clustering of genes altered in lipid and carbohydrate
metabolism from network 1.
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Figure 4.9:

Pathway analysis network involving differentially expressed genes
from carbohydrate and lipid metabolism groups in metabolic
disorders-network 2
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Figure 4.10:

4.4.3

Hierarchical clustering of the two groups for altered genes
included in network 2

Real Time PCR
To confirm the array data for the gene expression pattern of the molecules

involved in RAS, we performed a quantitative PCR using the total RNA isolated from the
heart tissues. Three tissues from each group were taken for analysis. The results are
shown as the fold difference in the treated tissue samples in comparison to the control
after normalization with the house keeping gene. A similar pattern was observed in the
qPCR. We saw a reduction in Angiotensinogen and ACE expression, but the other genes
did not show a statistical difference in the expression profile. The data is given in figure
4.11.
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Figure 4.11:

Real-Time PCR validation of array expression analysis.
Expression levels of the components of RAS pathway determined
using RT PCR. The data shown here is the relative fold difference
to the untreated samples after normalization to the house keeping
gene ȕ actin. * P<0.05

4.5

Discussion

This huge amount of data obtained from heart tissues of an early hypertensive
model with its respective controls will serve as a databank for mining of the
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transcriptome at a gene level or an exon level. In order to have a better understanding of
the changes in the insulin resistant genes, we looked at genes that were involved in
insulin resistance or insulin sensitivity.
The genes involved in the RAS pathway did not show much change in the
expression profile. However, we observed that angiotensinogen (5-fold), AT1a receptor
and ACE (2-fold) was downregulated in the treated animals. This could be attributed to
the exogenous infusion of Ang II which would slow down the inherent RAS signaling in
the tissue as a compensatory mechanism.
The orphan nuclear receptor PPARȖ is a transcription factor that is implicated in
the expression of several genes involved in lipid and carbohydrate homeostasis and
therefore plays an important role in metabolic disorders such as dyslipidemia, insulin
resistance, atherosclerosis and coronary artery disease. The importance of this orphan
receptor is further established by a group of molecules called the thiazolidinediones
(TZD), which are oral insulin sensitizers that are currently used to improve insulin
sensitivity, that act as ligands for the receptor. In addition to insulin sensitization, TZDs
can also improve hypertensive and atherosclerotic conditions by repressing the AT1
receptor gene or by reducing the adhesion molecules VCAM and ICAM. Ang II infusion
and AT1R activation are known to reduce the levels of PPARȖ mRNA and protein levels
in a mouse model of atherosclerosis (14-19).
In our study, we observed a reduction in the mRNA levels of PPARȖ in heart
tissues treated with Ang II and NaCl. Reduction in PPARȖ can affect the transcription of
various insulin sensitizing molecules involved in glucose uptake (c-Cbl associated
protein, Glut4), lipid uptake and storage (CD36, aP2, LPL, FATP, and acylCoA
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synthetase) and energy expenditure (GyK, UCP1 and UCP3). The molecules involved in
energy expenditure are reduced in the heart tissues obtained from the experimental group
in our study. Glycerol kinase upregulation results in a reduced level of free fatty acids in
circulation. FFAs are known to cause insulin resistance. Glycerol kinase converts
glycerol released from triglycerides into glycerol phosphate. The glycerol phosphate then
facilitates the reincorporation of FFAs into triglycerides at an energy cost. Uncoupling
proteins improves energy expenditure by allowing the proton flow across the
mitochondrial membrane bypassing the ATPase and thereby diverting potential energy
into heat rather than ATP. In diabetic patients, increased energy expenditure should be
therapeutically beneficial.
In addition to glucose and lipid homeostasis, PPARȖ plays an important role in
transcriptional regulation of adipocytokines. As discussed in the previous chapter, one of
the most interesting observations was the downregulation of the adipocytokinesadiponectin, leptin and resistin. These three molecules are known to play an important
role in mediating insulin sensitivity or insulin resistance. PPARȖ expression is markedly
downregulated in insulin resistant stages. In our array analysis, we see a sharp reduction
of PPARȖ in heart tissues. Adiponectin is a potent anti-inflammatory, antiatherogenic
molecule with insulin sensitizing effects on tissues involved in glucose metabolism.
Levels of adiponectin are decreased considerably in diabetic patients. PPARȖ agonists,
TZDs, are known to increase the levels of adiponectin mRNA. Therefore, they are
implicated in transcriptional regulation of adiponectin. PPARȖ is also known to affect the
expression of leptin. Leptin is downregulated in diabetic conditions (20). Levels of leptin
reduce in parallel to PPARȖ reduction in fasting. The exact mechanism of PPARȖ
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mediated regulation of leptin is unclear; however our observations suggest that changes
in PPARȖ expression could contribute to changes in leptin expression or that both are
under the regulation of common transcription factors. Resistin is another recently
discovered adipocytokine that is known to induce insulin resistance in obesity. Recent
studies have shown that resistin expression goes up in cardiomyocytes that are subjected
to mechanical stretch. PPARȖ agonists that reduce insulin resistance are known to
downregulate the expression of resistin thereby improving insulin sensitivity. In our
studies, we see a reduction in the adiponectin and leptin levels which suggest a higher
risk for development of insulin resistance. At the same time, we see a reduction in the
resistin mRNA expression levels also in these heart tissues. Transcriptional regulation of
resistin is a balance between the two transcription factors- PPARȖ and CEBPĮ. CEBPĮ is
known to bind to the promoter region of resistin that result in activation of transcription
coactivators and histone acetylation. However, PPARȖ is known to have a negative effect
on resistin transcription by reducing histone acetylation associated with CEBPĮ binding
(21). In this case, we see a reduction in the expression of both the transcription factorsPPARȖ and CEBPĮ. This could be one reason to explain the reduction in the resistin
levels in hypertensive rat heart even though there is a reduction in PPARȖ. On the
contrary, there could be another mechanism that could be playing a role in the reduction
in resistin levels. Since increased resistin is a poor prognosis for heart disease and insulin
resistance, pathways that result in inhibition of resistin expression provide potential
targets for drug development to treat insulin resistance.
Angiotensin II mediates endothelial dysfunction and promotes vascular
inflammation and atherogenesis(22). Reactive oxygen species play an important role in
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these processes. Ang II can also stimulate cytosolic and mitochondrial oxidation
eventually leading to mitochondrial dysfunction in cardiac tissues. This will in turn result
in the production of more ROS (23-25). Overexpression of ROS is implicated in the
development of insulin resistance (26). AT1 receptor blockers are known to improve
mitochondrial function in hypertensive conditions (27). In our analysis we saw an
increase in the expression of the genes PGC1Į and Tfam that are involved in
mitochondrial biogenesis. However, we saw a reduction in the expression of
mitochondrial uncoupling proteins that are members of the family of mitochondrial anion
carrying proteins. We saw a decrease in the expression of UCP1 and UCP3 that are
involved in energy metabolism. In addition to energy dissipation in the form of heat,
UCP3 is also known to export the long chain fatty acids from the mitochondria in skeletal
muscle (28). This is of physiological importance as accumulation of long chain fatty
acids in the matrix does not undergo ȕ oxidation and will lead to mitochondrial damage.
Heart derives energy for ATP production from fatty acid oxidation and to a lesser extent
from glucose oxidation. The fatty acid uptake and utilization is a well balanced
mechanism and a small fluctuation in the levels of fatty acid uptake or oxidation is
sufficient for intramyocellular lipid accumulation and reduced mitochondrial oxidation.
We observe a reduction in the gene expression of CPT-1, which is a mitochondrial
enzyme that is involved in fatty acid uptake into the mitochondria for oxidative
phosphorylation and AMPK which is an enzyme that is important in fatty acid
metabolism. AMPK is an enzyme that is upregulated when the ATP:AMP ratio decreases
under stress conditions and this upregulation helps in increased fatty acid metabolism and
increased fuel availability for the heart. Similarly we see a reduction in aconitase, which
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is an enzyme involved in Krebs’s cycle. A number of genes involved in fatty acid
transport and mitochondrial oxidative of fatty acids were reduced in the hypertensive
heart tissues. Furthermore, the levels of UCP3 are reduced in insulin resistant conditions
suggesting a role for the transporter in the development of mitochondrial damage in
diabetic patients. UCP2 on the other hand showed an increase in these hypertensive
tissues. UCP2 is known to induce insulin resistance by affecting insulin secretion from
the beta cells of the pancreas. Thus Ang II acting via mitochondrial anion transporters
seems to play a role in stress mediated development of insulin resistance. A signaling
mechanism for mitochondrial dysfunction mediated insulin resistance is given in figure
4.12.

FABP
Lipe
CIDEC
PLIN

ACCA
DGAT
ATP CITRATE LYASE

CPT1
AMPK
Aconitase
UCP1
UCP3

Imbalance between uptake and utilization= intramyocellular lipid accumulation

Figure 4.12:

A possible mechanism for mitochondrial dysfunction mediated
insulin resistance in hypertensive heart.
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As was described in the tables 4.2-4.5, we see changes in the expression patterns
of a set of genes that can reduce the negative effects of insulin resistance and
hypertension. In contrast, changes in the expression pattern of those genes that can result
in hypertension or insulin resistance was also observed. Thus our analysis of the
transcriptional changes occurring in the heart tissue of a hypertensive rodent model
shows that there are two signaling mechanisms that are exerting their effects on the
organ; one that induce insulin resistance and one that attempt to counter this transition.
This analysis has begun to unravel a set of genes that might be beneficial as targets for
treatment. For example, we see a reduction in the resistin gene (Retn) which is usually a
marker for insulin resistance. Even though we do not know the exact mechanism for this
down-regulation of Retn, it provides an initial step in directing the research in a new area.
An early hypertension model may not show gross differences in cellular
transcription in the heart tissue. However, alterations in the gene expression profile are
valuable in the management and mechanistic understanding of the disease. Since there is
an attempt to move from studies of single diseases to experiments aimed at determining
common and distinct expression patterns occurring in similar phenotypes arising through
different mechanisms, our study enable us to identify distinct expression signatures
associated with hypertension and insulin resistance.
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CHAPTER V
SUMMARY

A number of studies to understand the cross talk between Ang II and insulin
signaling pathways provided the motivation for the current work. Until now, all the
studies done showed that administration of Ang II in an in vivo or in vitro system results
in changes in the downstream signaling of the insulin receptor. Kolhe et.al showed that
there is a receptor level association between the Ang II receptor AT1 and IR which
results in a reduction in the amount of insulin binding to the insulin receptor. In this
study, we demonstrate a physical association between the two types of Ang II receptors
and the IR as analyzed using yeast two-hybrid assay. We also show that in an early
hypertension model of rat, the heart tissue shows an association between the AT1/AT2
receptors and the IR. This association between the receptors also alters the insulin
mediated signaling in the heart tissue as observed in the changes in the phosphorylation
pattern of the IR and IRS 1. Hyperglycemia was absent in these animals even with the
altered insulin signaling pathway. In addition to these observations, studies performed to
evaluate the transcriptional changes occurring due to Ang II and NaCl administration
suggests two pathways being activated- one in the direction of insulin sensitization and
other in the direction of insulin resistance. Thus our study proves that the transition from
a hypertensive state to an insulin resistant status starts at an early stage in an individual
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and a prolonged exposure to the factor that triggers this event (genetic or environmental)
might result in a full blown disease condition. Therefore, it is crucial to identify the risk
factors associated with hypertension and insulin resistance even before the existence of
visible symptoms appear for better prevention and treatment of the condition before it
develops into a metabolic syndrome.

5.1

Future work

It is desirable to evaluate the effect of Ang II and NaCl administration for longer
periods of time to see the pathways that are being drastically affected. Also, the effects of
Ang II treatment and NaCl treatment should be separated out as both can individually
cause hypertension. There is also a need to closely investigate the causes leading to the
transcriptional changes occurring under these conditions to obtain more accurate results
that might help in target development and therapeutic strategies.
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